

AUTHOR INDEX FOR VOLUME 40

A

- Adachi, K., *see* Andrea, J. E., 495
 Addya, K., *see* Siemens, I. R., 717
 Adelman, J. P., *see* Hurst, R. S., 572
 Adler, H. J., *see* Siemens, I. R., 717
 Aftab, D. T., Ballas, L. M., Loomis, C. R., and Hait, W. N. Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C, 798
 Ahluwalia, G. S., *see* Hartman, N. R., 118
 Akman, S., *see* Forrest, G. L., 502
 Aksoy, S., *see* McKinney, M., 1014
 Aktories, K., *see* Grimminger, F., 563
 Ali, H., *see* Hide, M., 473
 Allen, J. M., *see* Hughes, R. J., 974
 Anderson, R., Van Rensburg, C. J., Jooné, G. K., and Lessing A. Auranofin inactivates phosphofructokinase in human neutrophils leading to depletion of intracellular ATP and inhibition of superoxide generation and locomotion, 427
 Anderson, R. S., *see* Ling, Y.-H., 508
 Andrea, J. E., Adachi, K., and Morgan, A. R. Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs: Quantitation of catalytic activity and DNA cleavage, 495
 Arena, J. P., Liu, K. K., Paress, P. S., and Cully, D. F. Avermectin-sensitive chloride currents induced by *Caenorhabditis elegans* RNA in xenopus oocytes, 368
 Atkinson, B., *see* Minneman, K. P., 523
 Azuma, M., *see* Morita, K., 112

B

- Bach, T. J., *see* Evans, J. F., 22
 Baden, D. G., *see* Trainer, V. L., 988
 Baden, H. A., *see* Duffel, M. W., 36
 Ballas, L. M., *see* Aftab, D. T., 798
 Barber, R., *see* Stickle, D., 276
 Baron, J., *see* Duffel, M. W., 36
 Bauer, P. H., *see* Pobiner, B. F., 156
 Baukal, A. J., *see* Bella, T., 401
 Beattie, K. L., *see* Ling, Y.-H., 508
 Beaune, P. H., *see* Srivastava, P. K., 69
 Beaven, M. A., *see* Hide, M., 473
 Begleiter, A., Leith, M. K., and Pan, S.-S. Mechanisms for the modulation of alkylating activity by the quinone group in quinone alkylating agents, 454
 Bella, T., Baukal, A. J., Eng, S., and Catt, K. J. Angiotensin II receptor subtypes and biological responses in the adrenal cortex and medulla, 401
 Bernard, B. A., *see* Delescluse, C., 556
 Bertino, J. R., *see* Li, W.-W., 854
 Binder, T. P., *see* Duffel, M. W., 36
 Birnbaumer, M., *see* Johnson, J. A., 539
 Bisacchi, G. S., *see* Yamanaka, G., 446
 Blaustein, M. P., Rogowski, R. S., Schneider, M. J., and Krueger, B. K. Polypeptide toxins from the venoms of old world and new world scorpions preferentially block different potassium channels, 932
 Boobis, A. R., *see* De Matteis, F., 686
 Bornheim, L. M., and Correia, M. A. Purification and characterization of the major hepatic cannabinoid hydroxylase in the mouse: A possible member of the cytochrome P-450IIC subfamily, 228
 Boucher, R. C., *see* Brown, H. A., 648
 Boynton, A. L., *see* Honkanen, R. E., 577
 Brancheck, T. A., *see* Zgombick, J. M., 1036

- Brann, M. R., *see* Dörje, F., 459
 Brann, M. R., *see* Jones, S. V. P., 242
 Bridson, P. K., *see* Lloyd, R. V., 440
 Broder, S., *see* Hartman, N. R., 118
 Brovtina, N., *see* Voitenko, S., 180
 Brown, A. M., *see* Tagliatela, M., 299
 Brown, H. A., Lazarowski, E. R., Boucher, R. C., and Harden, T. K. Evidence that UTP and ATP regulate phospholipase C through a common extracellular 5'-nucleotide receptor in human airway epithelial cells, 648
 Bruinvels, A., *see* Hibert, M. F., 8
 Buck, M. A., *see* Wang, C.-D., 168
 Bürgin, M., *see* Christen, U., 390
 Busch, A. E., *see* Hurst, R. S., 572
 Buxton, I. L. O., *see* Zhang, L., 943, 952
 Bylund, D. B., *see* Simonneaux, V., 235

C

- Cabantchik, Z. I., *see* Lytton, S. D., 584
 Campillo, M., *see* Pardo, L., 980
 Camus, J., *see* Waelbroeck, M., 413
 Cardozo, M. G. and Hopfinger, A. J. Molecular mechanics and molecular dynamics studies of the intercalation of dynemicin-A with oligonucleotide models of DNA, 1023
 Carlson, C. D., *see* Fossom, L. H., 193
 Caron, M. G., *see* Schwinn, D. A., 619
 Catt, K. J., *see* Bella, T., 401
 Catterall, W. A., *see* Ragsdale, D. S., 756
 Catterall, W. A., *see* Trainer, V. L., 988
 Cavey, M. T., *see* Delescluse, C., 556
 Celentano, J. J., Gyenes, M., Gibbs, T. T., and Farb, D. H. Negative modulation of the γ -aminobutyric acid response by extracellular zinc, 766
 Chae, K., Gibson, M. K., and Korach, K. S. Estrogen receptor stereochemistry: Ligand binding orientation and influence on biological activity, 806
 Charleson, P., *see* Evans, J. F., 22
 Chaudhry, A., *see* Granneman, J. G., 895
 Cheng, Y.-C., *see* Ling, Y.-H., 508
 Christen, U., Bürgin, M., and Gut, J. Halothane metabolism: Immunochemical evidence for molecular mimicry of trifluoroacetylated liver protein adducts by constitutive polypeptides, 390
 Christophe, J., *see* Waelbroeck, M., 413
 Cianci, C. W., *see* Terry, B. J., 591
 Clark, R. B., *see* Johnson, J. A., 539
 Clifford, D. B., *see* Zorumski, C. F., 45
 Coffman, B., *see* Styczynski, P., 80
 Colby, H. D., *see* Kossor, D. C., 321
 Comoglio, A., *see* De Matteis, F., 686
 Compton, D. R., *see* Thomas, B. F., 656
 Coon, M. J., *see* Peng, H.-M., 58
 Cooney, D. A., *see* Hartman, N. R., 118
 Cooper, C. L., *see* Jeffs, R. A., 85
 Cornwell, T. L., Pryzwansky, K. B., Wyatt, T. A., and Lincoln, T. M. Regulation of sarcoplasmic reticulum protein phosphorylation by localized cyclic GMP-dependent protein kinase in vascular smooth muscle cells, 923
 Correia, M. A., *see* Bornheim, L. M., 228
 Costa, E., *see* Vigé, X., 186
 Cotecchia, S., *see* Schwinn, D. A., 619
 Cresteil, T., *see* Lemoine, A., 211

Cully, D. F., and Pareess, P. S. Solubilization and characterization of a high affinity ivermectin binding site from *Caenorhabditis elegans*, 326

Cully, D. F., *see* Arena, J. P., 368

D

D'Angelo, D. D., *see* Harrison, J. K., 407

Darmon, M., *see* Delescluse, C., 556

David, C., and Fuchs, S. Antipeptide antibodies localize *N*-(4-azido-3-[¹²⁵I]iodophenethyl)piperone binding to the carboxyl-terminal proton of the D₂ dopamine receptor, 712

Dawson, S. J., *see* De Matteis, F., 686

Day, R. O., *see* Handel, M. L., 613

Dazin, P. F., *see* Mitsuhashi, M., 271

deFazio, A., *see* Handel, M. L., 613

De Léan, A., *see* Féthière, J., 915

Delescluse, C., Cavey, M. T., Martin, B., Bernard, B. A., Reichert, U., Maignan, J., Darmon, M., and Shroot, B. Selective high affinity retinoic acid receptor α or β - γ ligands, 556

De Matteis, F., Dawson, S. J., Boobis, A. R., and Comoglio, A. Inducible bilirubin-degrading system of rat liver microsomes: Role of cytochrome P450IA1, 686

Denison, M. S., *see* Helferich, W. G., 674

Diamond, I., *see* Nagy, L. E., 812

Dichter, M., *see* Raynor, K., 248

Ding, X., *see* Peng, H.-M., 58

Dissanayake, V. U. K., Hughes, J., and Hunter, J. C. Opioid binding sites in the guinea pig and rat kidney: Radioligand homogenate binding and autoradiography, 93

Dörje, F., Levey, A. I., and Brann, M. R. Immunological detection of muscarinic receptor subtype proteins (m1-m5) in rabbit peripheral tissues, 459

Doroshov, J., *see* Forrest, G. L., 502

Drewe, J. A., *see* Tagliatela, M., 299

Dudley, D. T., Hubbell, S. E., and Summerfelt, R. M. Characterization of angiotensin II (AT₂) binding sites in R3T3 cells, 360

Duffel, M. W., Binder, T. P., Hosie, L., Baden, H. A., Sanders, J. A., Knapp, S. A., and Baron, J. Purification, immunochemical characterization, and immunohistochemical localization of rat hepatic aryl sulfotransferase IV, 36

Dukelow, M., *see* Honkanen, R. E., 577

Duling, D. R., *see* Lloyd, R. V., 440

Duman, R. S., *see* Rimland, J., 869

Dyadyusha, G. G., *see* Voitenko, S., 180

E

Ebadi, M., *see* Simonneaux, V., 235

Eberhart, D. C., Gemzik, B., Halvorson, M. R., and Parkinson, A. Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin, 859

Eichelbaum, M., *see* Kroemer, H. K., 135

Eng, S., *see* Bella, T., 401

Eskuri, S., *see* Sill, J. C., 1006

Evans, J. F., Léveillé, C., Mancini, J. A., Prasit, P., Thérien, M., Zamboni, R., Gauthier, J. Y., Fortin, R., Charleson, P., MacIntyre, D. E., Luell, S., Bach, T. J., Meurer, R., Guay, J., Vickers, P. J., Rouzer, C. A., Gillard, J. W., and Miller, D. K. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors, 22

F

Farb, D. H., *see* Celentano, J. J., 766

Farb, D. H., *see* Wu, F.-S., 333

Fenselau, C., *see* Odell, G. B., 597

Féthière, J., and De Léan, A. Pharmacological evidence for the heterogeneity of atrial natriuretic factor-R₁ receptor subtype, 915

Field, A. K., *see* Yamanaka, G., 446

Fischer, C., *see* Kroemer, H. K., 135

Fischer, V., Haar, J. A., Greiner, L., Lloyd, R. V., and Mason, R. P. Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis, 846

Fluharty, S. J., *see* Siemens, I. R., 717

Forrest, G. L., Akman, S., Doroshov, J., Rivera, H., and Kaplan, W. D. Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity, 502

Fortin, R., *see* Evans, J. F., 22

Fossom, L. H., Carlson, C. D., and Tank, A. W. Stimulation of tyrosine hydroxylase gene transcription rate by nicotine in rat adrenal medulla, 193

Franklin, S. O., Zhu, Y.-S., Yoburn, B. C., and Inturrisi, C. E. Trans-synaptic activity regulates proenkephalin and tyrosine hydroxylase gene expression and the response to reserpine in the hamster adrenal, 515

Fraser, C. M., *see* Wang, C.-D., 168

Fraser, E. D., *see* Pobiner, B. F., 156

Fredholm, B. B., *see* Gerwins, P., 149

Fridland, A., *see* Hartman, N. R., 118

Friedman, J., *see* Johnson, J. A., 539

Fuchs, S., *see* David, C., 712

Fujita, T., *see* Tachikawa, E., 790

Furumachi, K., *see* Tachikawa, E., 790

Furuya, H., Meyer, U. A., Gelboin, H. V., and Gonzalez, F. J. Polymerase chain reaction-directed identification, cloning and quantification of human CYP2C18 mRNA, 375

G

Garrison, J. C., *see* Pobiner, B. F., 156

Gasiewicz, T. A., and Rucci, G. α -Naphthoflavone acts as an antagonist of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin by forming an inactive complex with the Ah receptor, 607

Gauthier, J. Y., *see* Evans, J. F., 22

Ged, C., *see* Srivastava, P. K., 69

Gee, K. W., and Lan, N. C. γ -Aminobutyric acid_A receptor complexes in rat frontal cortex and spinal cord show differential responses to steroid modulation, 995

Gelboin, H. V., *see* Furuya, H., 375

Gemizik, B., *see* Eberhart, D. C., 859

Gerfen, C. R., *see* Mahan, L. C., 1

Gergel, D., *see* Mišák, V., 435

Gerhardt, M. A., and Neubig, R. R. Multiple G_i protein subtypes regulate a single effector mechanism, 707

Gerwins, P., and Fredholm, B. B. Glucocorticoid receptor activation leads to up-regulation of adenosine A₁ receptors and down-regulation of adenosine A₂ responses in DDT₁ MF-2 smooth muscle cells, 149

Gibbs, T. T., *see* Celentano, J. J., 766

Gibbs, T. T., *see* Wu, F.-S., 333

Gibson, M. K., *see* Chae, K., 806

Gibson, V. A., *see* McKinney, M., 1014

Gillard, J. W., *see* Evans, J. F., 22

Giorgi-Renault, S., *see* Riou, J.-F., 699

Giraldo, J., *see* Pardo, L., 980

Glasel, J. A., *see* Ornatowska, M., 354

Golas, C. L., *see* Harper, P. A., 818

Gonzalez, F. J., *see* Furuya, H., 375

Gonzalez, F. J., *see* Tyndale, R. F., 63

Gordon, A. S., *see* Nagy, L. E., 812

Gottesman, M. M., *see* Lelong, I. H., 490

Graham, R. M., *see* Perez, D. M., 876

Granneman, J. G., Lahners, K. N., and Chaudhry, A. Molecular cloning and expression of the rat β_3 -adrenergic receptor, 895

Green, M., *see* Styczynski, P., 80

Greiner, L., *see* Fischer, V., 846

Grimminger, F., Sibelius, U., Aktories, K., Suttrop, N., and Seeger, W. Inhibition of cytoskeletal rearrangement by botulinum C2 toxin amplifies ligand-evoked lipid mediator generation in human neutrophils, 563

- Grondard, L., *see* Riou, J.-F., 699
Guay, J., *see* Evans, J. F., 22
Guengerich, F. P., *see* Srivastava, P. K., 69
Guengerich, F. P., *see* Yun, C.-H., 679
Gusovsky, F. Prostaglandin receptors in NIH 3T3 cells: Coupling of one receptor to adenylate cyclase and of a second receptor to phospholipase C, 633
Gut, J., *see* Christen, U., 390
Guzelian, P. S., *see* Kocarek, T. A., 203
Guzikowski, A. P., *see* Lelong, I. H., 490
Gyenes, M., *see* Celentano, J. J., 766

H

- Haar, J. A., *see* Fischer, V., 846
Haffey, M., *see* Yamanaka, G., 446
Hagen, M., *see* Yamanaka, G., 446
Hagen, M. E., *see* Terry, B. J., 591
Hait, W. N., *see* Aftab, D. T., 798
Halligan, R. D., *see* Johnson, J. A., 539
Halvorson, M. R., *see* Eberhart, D. C., 859
Hamano, S., *see* Morita K., 112
Hamblin, M. W., and Metcalf, M. A. Primary structure and functional characterization of a human 5-HT_{1D}-type serotonin receptor, 143
Hamel, E., *see* Lin, C. M., 827
Han, C., and Minneman, K. P. Interaction of subtype-selective antagonists with α_1 -adrenergic receptor binding sites in rat tissues, 531
Handel, M. L., deFazio, A., Watts, C. K. W., Day, R. O., and Sutherland, R. L. Inhibition of DNA binding and transcriptional activity of a nuclear receptor transcription factor by aurothiomalate and other metal ions, 613
Hanna, J. L., *see* Williams, K., 774
Harden, T. K., *see* Brown, H. A., 648
Harden, T. K., *see* Jeffs, R. A., 85
Harden, T. K., *see* Waldo, G. L., 480
Haring, R., Pellegrini-Giampietro, D. E., Zukin, S. R., Zukin, R. S., and Scheideler, M. A. High efficiency reconstitution of a phencyclidine/MK-801 receptor binding site solubilized from rat forebrain membranes, 666
Harper, P. A., Golas, C. L., and Okey, A. B. Ah Receptor in mice genetically "nonresponsive" for cytochrome P4501A1 induction: Cytosolic Ah receptor, transformation to the nuclear binding state, and induction of aryl hydrocarbon hydroxylase by halogenated and nonhalogenated aromatic hydrocarbons in embryonic tissues and cells, 818
Harrison, J. K., D'Angelo, D. D., Zeng, D., and Lynch, K. R. Pharmacological characterization of rat α_2 -adrenergic receptors, 407
Hartig, P. R., *see* Zgombick, J. M., 1036
Hartman, N. R., Ahluwalia, G. S., Cooney, D. A., Mitsuya, H., Kageyama, S., Fridland, A., Broder, S., and Johns, D. G. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine, 118
Haugland, R. P., *see* Lelong, I. H., 490
Heilman, C. J., *see* Jones, S. V. P., 242
Helferich, W. G., and Denison, M. S. Ultraviolet photoproducts of tryptophan can act as dioxin agonists, 674
Helissey, P., *see* Riou, J.-F., 699
Hellwig, B., and Joost, H. G. Differentiation of erythrocyte (GLUT1), liver-(GLUT2) and adipocyte-type (GLUT4) glucose transporters by binding of the inhibitory ligands, cytochalasin B, forskolin, dipyrindamol and isobutylmethylxanthine, 383
Henderson, G., *see* Kennedy, C., 1000
Hesson, D. P., *see* Lin, C. M., 827
Hibert, M. F., Trumpp-Kallmeyer, S., Bruinvels, A., and Hoflack, J. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors, 8
Hide, M., Ali, H., Price, S. R., Moss, J., and Beaven, M. A. GTP-Binding protein G α_z : Its down-regulation by dexamethasone and

- its credentials as a mediator of antigen-induced responses in RBL-2H3 cells, 473
Hirning, L. D., *see* Werth, J. L., 742
Hitchcock, M. J. M., *see* Zhu, Z., 838
Hoflack, J., *see* Hibert, M. F., 8
Hopfinger, A. J., *see* Cardozo, M. G., 1023
Hokin, L. E., *see* Reichman, M., 547
Honkanen, R. E., Dukelow, M., Zwiller, J., Moore, R. E., Khatra, B. S., and Boynton, A. L. Cyanobacterial nodularin is a potent inhibitor of type 1 and type 2A protein phosphatases, 577
Horowitz, B., *see* Zhang, L., 943
Hosey, M. M., *see* Mayanil, C. S. K., 900
Hosey, M. M., *see* Richardson, R. M., 908
Hosie, L., *see* Duffel, M. W., 36
Howard, M. J., *see* Hughes, R. J., 974
Hubbell, S. E., *see* Dudley, D. T., 360
Hughes, A. R., Bird, G. St. J., Obie, J. F., Thastrup, O., and Putney, J. W., Jr. Role of inositol (1,4,5)trisphosphate in epidermal growth factor-induced Ca²⁺ signaling in A431 cells Bird, G. St. J., *see* Hughes, A. R., 254
Hughes, J., *see* Dissanayake, V. U. K., 93
Hughes, R. J., Howard, M. J., Allen, J. M., and Insel, P. A. Decreased β_2 -adrenergic receptor mRNA expression in receptor-deficient S49 lymphoma cells, 974
Hunter, J. C., *see* Dissanayake, V. U. K., 93
Hurst, R. S., Busch, A. E., Kavanaugh, M. P., Osborne, P. B., North, R. A., and Adelman, J. P. Identification of amino acid residues involved in dendrotoxin block of rat voltage-dependent potassium channels, 572

I

- Iida, A., *see* Tachikawa, E., 790
Imakura, Y., *see* Sakurai, H., 965
Inaba, T., *see* Tyndale, R. F., 63
Insel, P. A., *see* Hughes, R. J., 974
Inturrisi, C. E., *see* Franklin, S. O., 515

J

- Jacobson, K. A., *see* Ramkumar, V., 639
Jaiswal, N., Jaiswal, R. K., and Malik, K. U. Muscarinic receptor-mediated prostacyclin and cGMP synthesis in cultured vascular cells, 101
Jaiswal, R. K., *see* Jaiswal, N., 101
Jeffs, R. A., Cooper, C. L., and Harden, T. K. Solubilization of a guanine nucleotide-sensitive form of the P_{2Y} purinergic receptor, 85
Jiang, J. B., *see* Lin, C. M., 827
Johns, D. G., *see* Hartman, N. R., 118
Johnson, E. F., *see* Lawton, M. P., 692
Johnson, J. A., Friedman, J., Halligan, R. D., Birnbaumer, M., and Clark, R. B. Sensitization of adenylyl cyclase by P₂ purinergic and M5 muscarinic receptor agonists in L cells, 539
Joho, R. H., *see* Tagliatela, M., 299
Jones, S. V. P., Heilman, C. J., and Brann, M. R. Functional responses of cloned muscarinic receptors expressed in CHO-K1 cells, 242
Jooné, G. K., *see* Anderson, R., 427
Joost, H. G., *see* Hellwig, B., 383

K

- Kageyama, S., *see* Hartman, N. R., 118
Kalow, W., *see* Tyndale, R. F., 63
Kang, G. J., *see* Lin, C. M., 827
Kaplan, W. D., *see* Forrest, G. L., 502
Kashimoto, T., *see* Tachikawa, E., 790
Kavanaugh, M. P., *see* Hurst, R. S., 572
Kennedy, C. and Henderson, G. μ -Opioid receptor inhibition of calcium current: Development of homologous tolerance in single SH-SY5Y cells after chronic exposure to morphine *in vitro*, 1000

- Khatra, B. S., *see* Honkanen, R. E., 577
 Khodorov, B., *see* Zilberter, Y., 337
 Kim, S. G., Reddy, S. L., States, J. C., and Novak, R. F. Pyridine effects on expression and molecular regulation of the cytochrome P450IA gene subfamily, 52
 Kirsch, G. E., *see* Tagliatala, M., 299
 Klapper, D. G., *see* Waldo, G. L., 480
 Knapp, S. A., *see* Duffel, M. W., 36
 Kocarek, T. A., Schuetz, E. G., and Guzelian, P. S. Selective induction of cytochrome P450e by kepone (chlordecone) in primary cultures of adult rat hepatocytes, 203
 Kominami, S., *see* Kossor, D. C., 321
 Korach, K. S., *see* Chae, K., 806
 Kossor, D. C., Kominami, S., Takemori, S., and Colby, H. D. Role of the steroid 17 α -hydroxylase in spironolactone-mediated destruction of adrenal cytochrome P-450, 321
 Kroemer, H. K., Fischer, C., Meese, C. O., and Eichelbaum, M. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: *In vitro* evaluation of the mechanism, 135
 Kronbach, T., *see* Lawton, M. P., 692
 Krueger, B. K., *see* Blaustein, M. P., 932
 Kulmacz, R. J., Palmer, G., and Tsai, A.-L. Prostaglandin H synthase: Perturbation of the tyrosyl radical as a probe of anticyclooxygenase agents, 833
- L**
- Lahnert, K. N., *see* Granneman, J. G., 895
 Lan, N. C., *see* Gee, K. W., 995
 Lapetina, E. G., *see* Schwinn, D. A., 619
 Lauriault, V. V. M., and O'Brien, P. J. Molecular mechanism for prevention of *N*-acetyl-*p*-benzoquinoneimine cytotoxicity by the permeable thiol drugs diethyldithiocarbamate and dithiothreitol, 125
 Lawton, M. P., Kronbach, T., Johnson, E. F., and Philpot, R. M. Properties of expressed and native flavin-containing monooxygenases: Evidence of multiple forms in rabbit liver and lung, 692
 Lazarowski, E. R., *see* Brown, H. A., 648
 Lee, K.-H., *see* Sakurai, H., 965
 Lefkowitz, R. J., *see* Schwinn, D. A., 619
 Legendre, P., and Westbrook, G. L. Ifenprodil blocks *N*-methyl-D-aspartate receptors by a two-component mechanism, 289
 Leith, M. K., *see* Begleiter, A., 454
 Lelong, I. H., Guzikowski, A. P., Haugland, R. P., Pastan, I., Gottesman, M. M., and Willingham, M. C. Fluorescent verapamil derivative for monitoring activity of the multidrug transporter, 490
 Lemoine, A., Williams, D. E., Cresteil, T., and Leroux, J.-P. Hormonal regulation of microsomal flavin-containing monooxygenase: Tissue-dependent expression and substrate specificity, 211
 Leroux, J.-P., *see* Lemoine, A., 211
 Lessing, A., *see* Anderson, R., 427
 Léveillé, C., *see* Evans, J. F., 22
 Levey, A. I., *see* Dörje, F., 459
 Li, M., *see* Wall, S. J., 783
 Li, M., Yasuda, R. P., Wall, S. J., Wellstein, A., and Wolfe, B. B. Distribution of m2 muscarinic receptors in rat brain using antisera selective for m2 receptors, 28
 Li, W.-W., Lin, J. T., Schweitzer, B. I., and Bertino, J. R. Mechanisms of sensitivity and natural resistance to antifolates in methylcholanthrene-induced rat sarcoma, 854
 Libman, J., *see* Lytton, S. D., 584
 Liggett, S. B., *see* Schwinn, D. A., 619
 Lin, C. M., Kang, G. J., Roach, M. C., Jiang, J. B., Hesson, D. P., Luduena, R. F., and Hamel, E. Investigation of the mechanism of the interaction of tubulin with derivatives of 2-styrylquinazolin-4(3H)-one, 827
 Lin, J. T., *see* Li, W.-W., 854
 Lincoln, T. M., *see* Cornwell, T. L., 923
 Lindstrom, J., *see* Whiting, P., 463
 Ling, Y.-H., Nelson, J. A., Cheng, Y.-C., Anderson, R. S., and Beattie, K. L. 2'-Deoxy-6-thioguanosine 5'-triphosphate as a substrate for purified human DNA polymerases and calf thymus terminal deoxynucleotidyltransferase *in vitro*, 508
 Liu, K. K., *see* Arena, J. P., 368
 Lloyd, R. V., Duling, D. R., Rumyantseva, G. V., Mason, R. P., and Bridson, P. K. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical, 440
 Lloyd, R. V., *see* Fischer, V., 846
 Loomis, C. R., *see* Aftab, D. T., 798
 Lorenz, W., *see* Schwinn, D. A., 619
 Lovinger, D. M., and White, G. Ethanol potentiation of 5-hydroxytryptamine₃ receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons, 263
 Luduena, R. F., *see* Lin, C. M., 827
 Luell, S., *see* Evans, J. F., 22
 Luthin, G. R., *see* Matesic, D. F., 347
 Lynch, K. R., *see* Harrison, J. K., 407
 Lytton, S. D., Cabantchik, Z. I., Libman, J., and Shanzer, A. Reversed siderophores as antimalarial agents. II. Selective scavenging of Fe(III) from parasitized erythrocytes by a fluorescent derivative of desferal, 584
- M**
- Macchi, M., *see* Zgombick, J. M., 1036
 MacIntyre, D. E., *see* Evans, J. F., 22
 Mah, S. J., *see* Siemens, I. R., 717
 Mahan, L. C., McVittie, L. D., Smyk-Randall, E. M., Nakata, H., Monsma, F. J., Jr., Gerfen, C. R., and Sibley, D. R. Cloning and expression of an A₁ adenosine receptor from rat brain, 1
 Maignan, J., *see* Delescluse, C., 556
 Malik, K. U., *see* Jaiswal, N., 101
 Mancini, J. A., *see* Evans, J. F., 22
 Manning, D. R., *see* Matesic, D. F., 347
 Martell, K. J., Vatsis, K. P., and Weber, W. W. Molecular genetic basis of rapid and slow acetylation in mice, 218
 Martin, B., *see* Delescluse, C., 556
 Martin, B. R., *see* Thomas, B. F., 656
 Martin, M., *see* Pardo, L., 980
 Mason, R. P., *see* Fischer, V., 846
 Mason, R. P., *see* Lloyd, R. V., 440
 Matesic, D. F., Manning, D. R., and Luthin, G. R. Tissue-dependent association of muscarinic acetylcholine receptors with guanine nucleotide-binding regulatory proteins, 347
 Mayanil, C. S. K., Richardson, R. M., and Hosey, M. M. Subtype-specific antibodies for muscarinic cholinergic receptors. I. Characterization using transfected cells and avian and mammalian cardiac membranes, 900
 Mayanil, C. S. K., *see* Richardson, R. M., 908
 McClue, S. J., and Milligan, G. Molecular interaction of the human α_2 -C10-adrenergic receptor, when expressed in rat-1 fibroblasts, with multiple pertussis toxin-sensitive guanine nucleotide-binding proteins: Studies with site-directed antisera, 627
 McGeever-Rubin, B., *see* Yamanaka, G., 446
 McKinney, M., Miller, J. H., Gibson, V. A., Nickelson, L., and Aksoy, S. Interactions of agonists with M2 and M4 muscarinic receptor subtypes mediating cyclic AMP inhibition, 1014
 McVittie, L. D., *see* Mahan, L. C., 1
 Meeley, M. P., *see* Regunathan, S., 884
 Meerman, J. H. N., *see* Noort, D., 316
 Meese, C. O., *see* Kroemer, H. K., 135
 Meijer, E. A., *see* Noort, D., 316
 Menniti, F. S., Takemura, H., Oliver, K. G., and Putney, J. W., Jr. Different modes of regulation for receptors activating phospholipase C in the rat pancreatoma cell line AR4-2J, 727
 Metcalf, M. A., *see* Hamblin, M. W., 143
 Meurer, R., *see* Evans, J. F., 22

- Meyer, U. A., *see* Furuya, H., 375
Middleton, J. P., *see* Schwinn, D. A., 619
Miki, T., *see* Sakurai, H., 965
Miller, D. K., *see* Evans, J. F., 22
Miller, J. H., *see* McKinney, M., 1014
Milligan, G., *see* McClue, S. J., 627
Minneman, K. P., and Atkinson, B. Interaction of subtype-selective antagonists with α_1 -adrenergic receptor-mediated second messenger responses in rat brain, 523
Minneman, K. P., *see* Han, C., 531
Mišik, V., Staško, A., Gergel, D., and Ondriaš, K. Spin-trapping and antioxidant properties of illuminated and nonilluminated nifedipine and nimodipine in heart homogenate and model system, 435
Mitsuhashi, M., Mitsuhashi, T., Dazin, P. F., and Payan, D. G. Agonistic activities of histamine-albumin conjugates at histamine H_2 receptors on human HL-60 promyelocytic leukemia cells, 271
Mitsuhashi, T., *see* Mitsuhashi, M., 271
Mitsuya, H., *see* Hartman, N. R., 118
Mogilevsky, W. S., *see* Odell, G. B., 597
Molinoff, P. B., *see* Williams, K., 774
Monsma, F. J., Jr., *see* Mahan, L. C., 1
Moore, R. E., *see* Honkanen, R. E., 577
Morgan, A. R., *see* Andrea, J. E., 495
Morita, K., Teraoka, K., Azuma, M., Oka, M., and Hamano, S. Tetrodotoxin-insensitive Na^+ channel activator palytoxin inhibits tyrosine uptake into cultured bovine adrenal chromaffin cells, 112
Morris, A. J., *see* Waldo, G. L., 480
Moss, J., *see* Hide, M., 473
Mulder, G. J., *see* Noort, D., 316
- N**
- Nagaoka, Y., *see* Tachikawa, E., 790
Nagy, L. E., Diamond, I., and Gordon, A. S. cAMP-Dependent protein kinase regulates inhibition of adenosine transport by ethanol, 812
Nakata, H., *see* Mahan, L. C., 1
Narasimhan, T. R., Safe, S., Williams, H. J., and Scott, A. I. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17 β -estradiol-induced glucose metabolism in MCF-7 human breast cancer cells: ^{13}C nuclear magnetic resonance spectroscopy studies, 1029
Near, J. A., *see* Vincent, M. S., 889
Nelson, J. A., *see* Ling, Y.-H., 508
Nen, W., *see* Reichman, M., 547
Nestler, E. J., *see* Rimland, J., 869
Neubig, R. R., *see* Gerhardt, M. A., 707
Nickelson, L., *see* McKinney, M., 1014
Nickolson, V. J., *see* Tam, S. W., 16
Niznik, H. B., *see* Tyndale, R. F., 63
Noort, D., Meijer, E. A., Visser, T. J., Meerman, J. H. N., Van der Marel, G. A., van Boom, T. H., and Mulder, G. J. Selective inhibition of glucuronidation by 2,2,2-triphenylethyl-UDP in isolated rat hepatocytes: Conjugation of harmol, 3,3',5-triiodothyronine, and *N*-hydroxy-2-acetylaminofluorene, 316
North, R. A., *see* Hurst, R. S., 572
Northup, J. K., *see* Pobiner, B. F., 156
Novak, R. F., *see* Kim, S. G., 52
- O**
- Obie, J. F., *see* Hughes, A. R., 254
O'Brien, P. J., *see* Lauriault, V. V. M., 125
Odell, G. B., Mogilevsky, W. S., Smith, P. B. W., and Fenselau, C. Identification of glutathione conjugates of the dimethyl ester of bilirubin in the bile of Gunn rats, 597
Oka, M., *see* Morita, K., 112
Okey, A. B., *see* Harper, P. A., 818
Olah, M. E., *see* Ramkumar, V., 639
Oliver, K. G., *see* Menniti, F. S., 727
Omeltchenko, I., *see* Voitenko, S., 180
Ondriaš, K., *see* Mišik, V., 435
Ornatowska, M., and Glasel, J. A. Stereospecificity of opiate receptors in a synchronized culture of NG108-15 cells probed with fluorescent anti-idiotypic antibodies, 354
Osborne, P. B., *see* Hurst, R. S., 572
- P**
- Pachter, J. A. Noncompetitive inhibition of inositol monophosphatase by K-76 monocarboxylic acid, 107
Page, S. O., *see* Schwinn, D. A., 619
Palmer, G., *see* Kulmacz, R. J., 833
Pan, S.-S., *see* Begleiter, A., 454
Pardo, L., Giraldo, J., Martín, M., and Campillo, M. Theoretical studies on the histamine H_2 receptor: Construction of a receptor model based on the structural properties of dimaprit and *N*[cf10] α -guanylhistamine, 980
Paress, P. S., *see* Arena, J. P., 368
Paress, P. S., *see* Cully, D. F., 326
Parkinson, A., *see* Eberhart, D. C., 859
Pastan, I., *see* Lelong, I. H., 490
Payan, D. G., *see* Mitsuhashi, M., 271
Pellegrini-Giampietro, D. E., *see* Haring, R., 666
Peng, H.-M., Porter, T. D., Ding, X., and Coon, M. J. Differences in the developmental expression of rabbit cytochromes P-450 2E1 and 2E2, 58
Perez, D. M., Piascik, M. T., and Graham, R. M. Solution-phase library screening for the identification of rare clones: Isolation of an α_{1D} -adrenergic receptor cDNA, 876
Philpot, R. M., *see* Lawton, M. P., 692
Piascik, M. T., *see* Perez, D. M., 876
Pobiner, B. F., Northup, J. K., Bauer, P. H., Fraser, E. D., and Garrison, J. C. Inhibitory GTP-binding regulatory protein G_{i3} can couple angiotensin II receptors to inhibition of adenylyl cyclase in hepatocytes, 156
Politi, D. M. T., and Rogawski, M. A. Glyburide-sensitive K^+ channels in cultured rat hippocampal neurons: Activation by cromakalim and energy-depleting conditions, 308
Porter, T. D., *see* Peng, H.-M., 58
Prasit, P., *see* Evans, J. F., 22
Price, S. R., *see* Hide, M., 473
Priestley, T., *see* Whiting, P., 463
Pryzwansky, K. B., *see* Cornwell, T. L., 923
Puig, J., *see* Styczynski, P., 80
Purnyn, S., *see* Voitenko, S., 180
Putney, J. W., Jr., *see* Hughes, A. R., 254
Putney, J. W., Jr., *see* Menniti, F. S., 727
- R**
- Ragsdale, D. S., Scheuer, T., and Catterall, W. A. Frequency and voltage-dependent inhibition of type IIA Na^+ channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs, 756
Ramkumar, V., Olah, M. E., Jacobson, K. A., and Stiles, G. L. Distinct pathways of desensitization of A_1 - and A_2 -adenosine receptors in DDT $_1$ MF-2 cells, 639
Rampe, D., *see* Zheng, W., 734
Raynor, K., Wang, H.-L., Dichter, M., and Reisine, T. Subtypes of brain somatostatin receptors couple to multiple cellular effector systems, 248
Reddy, S. L., *see* Kim, S. G., 52
Regunathan, S., Meeley, M. P., and Reis, D. J. Clonidine-displacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells, 884
Reichert, U., *see* Delescluse, C., 556
Reichman, M., Nen, W., and Hokin, L. E. Δ^9 -Tetrahydrocannabinol inhibits arachidonic acid acylation of phospholipids and triacylglycerols in guinea pig cerebral cortex slices, 547
Reis, D. J., *see* Regunathan, S., 884
Reisine, T., *see* Raynor, K., 248

- Richardson, R. M., Mayanil, C. S. K., and Hosey, M. M. Subtype-specific antibodies for muscarinic cholinergic receptors. II. Studies with reconstituted chick heart receptors and the FTP-binding protein G_o, 908
- Richardson, R. M., *see* Mayanil, C. S. K., 900
- Rimland, J., Xin, W., Sweetnam, P., Saijoh, K., Nestler, E. J., and Duman, R. S. Sequence and expression of a neuropeptide Y receptor cDNA, 869
- Riou, J.-F., Helissey, P., Grondard, L., and Giorgi-Renault, S. Inhibition of eukaryotic DNA topoisomerase I and II activities by indol-quinolinedione derivatives, 699
- Rivera, H., *see* Forrest, G. L., 502
- Roach, M. C., *see* Lin, C. M., 827
- Rogawski, M. A., *see* Politi, D. M. T., 308
- Rogowski, R. S., *see* Blaustein, M. P., 932
- Rominger, D., *see* Tam, S. W., 16
- Rosenberg, R. L., *see* Wang, Y., 750
- Rouzer, C. A., *see* Evans, J. F., 22
- Rucci, G., *see* Gasiewicz, T. A., 607
- Rudnick, G., and Wall, S. C. Binding of the cocaine analog 2 β [³H] carboxy-methoxy-3 β -(4-fluorophenyl)tropane to the serotonin transporter, 421
- Rumyantseva, G. V., *see* Lloyd, R. V., 440
- S**
- Safe, S., *see* Narasimhan, T. R., 1029
- Saijoh, K., *see* Rimland, J., 869
- Sakurai, H., Miki, T., Imakura, Y., Shibuya, M., and Lee, K.-H. Metal- and photo-induced cleavage of DNA by podophyllotoxin, etoposide, and their related compounds, 965
- Sanders, J. A., *see* Duffel, M. W., 36
- Schechter, L. E., *see* Zgombick, J. M., 1036
- Scheideler, M. A., *see* Haring, R., 666
- Scheuer, T., *see* Ragsdale, D. S., 756
- Schneider, M. J., *see* Blaustein, M. P., 932
- Schoepfer, R., *see* Whiting, P., 463
- Schuetz, E. G., *see* Kocarek, T. A., 203
- Schweitzer, B. I., *see* Li, W.-W., 854
- Schwinn, D. A., Page, S. O., Middleton, J. P., Lorenz, W., Liggett, S. B., Yamamoto, K., Lapetina, E. G., Caron, M. G., Lefkowitz, R. J., and Cotecchia, S. The α_{1C} adrenergic receptor: Characterization of signal transduction pathways and mammalian tissue heterogeneity, 619
- Scott, A. I., *see* Narasimhan, T. R., 1029
- Seeger, W., *see* Grimminger, F., 563
- Semus, S. F., *see* Thomas, B. F., 656
- Shanzer, A., *see* Lytton, S. D., 584
- Shibuya, M., *see* Sakurai, H., 965
- Shimada, T., *see* Yun, C.-H., 679
- Shroot, B., *see* Delaculose, C., 556
- Sibeliuss, U., *see* Grimminger, F., 563
- Sibley, D. R., *see* Mahan, L. C., 1
- Siemens, I. R., Adler, H. J., Addya, K., Mah, S. J., and Fluharty, S. J. Biochemical analysis of solubilized angiotensin II receptors from murine neuroblastoma N1E-115 cells by covalent cross-linking and affinity purification, 717
- Sill, J. C., Uhl, C., Eskuri, S., Van Dyke, R., and Tarara, J. Halothane inhibits agonist-induced inositol phosphate and Ca₂⁺ signaling in A7r5 cultured vascular smooth muscle cells, 1006
- Simonneaux, V., Ebadi, M., and Bylund, D. B. Identification and characterization of α_{2A} -adrenergic receptors in bovine pineal gland, 235
- Skok, V., *see* Voitenko, S., 180
- Smith, P. B. W., *see* Odell, G. B., 597
- Smyk-Randall, E. M., *see* Mahan, L. C., 1
- Sokolova, S., *see* Zilberter, Y., 337
- Sommadosi, F. P. Separation of human liver microsomal tolbutamide hydroxylase and (S)-Mephenytoin 4'-hydroxylase cytochrome P-450 enzymes, 69
- Staško, A., *see* Mišik, V., 435
- States, J. C., *see* Kim, S. G., 52
- Stickie, D., and Barber, R. Comparisons of the combined contributions of agonist binding frequency and intrinsic efficiency to receptor-mediated activation of adenylate cyclase, 276
- Stiles, G. L., *see* Ramkumar, V., 639
- Styczynski, P., Green, M., Puig, J., Coffman, B., and Tephly, T. Purification and properties of a rat liver phenobarbital-inducible 4-hydroxybiphenyl UDP-glucuronosyltransferase, 80
- Summerfelt, R. M., *see* Dudley, D. T., 360
- Sunahara, R., *see* Tyndale, R. F., 63
- Sutherland, R. L., *see* Handel, M. L., 613
- Suttorp, N., *see* Grimminger, F., 563
- Sweetnam, P., *see* Rimland, J., 869
- T**
- Tachikawa, E., Takahashi, S., Furumachi, K., Kashimoto, T., Iida, A., Nagaoka, Y., Fujita, T., and Takaishi, Y. Trichosporin-B-III, an α -aminoisobutyric acid-containing peptide, causes Ca²⁺-dependent catecholamine secretion from adrenal medullary chromaffin cells, 790
- Tagliatela, M., VanDongen, A. M. J., Drewe, J. A., Joho, R. H., Brown, A. M., and Kirsch, G. E. Patterns of internal and external tetraethylammonium block in four homologous K⁺ channels, 299
- Takahashi, S., *see* Tachikawa, E., 790
- Takaishi, Y., *see* Tachikawa, E., 790
- Takemori, S., *see* Kossor, D. C., 321
- Takemura, H., *see* Menniti, F. S., 727
- Tam, S. W., Rominger, D., and Nickolson, V. J. Novel receptor site involved in enhancement of stimulus-induced acetylcholine, dopamine, and serotonin release, 16
- Tank, A. W., *see* Fossom, L. H., 193
- Tarara, J., *see* Sill, J. C., 1006
- Tastenoy, M., *see* Waelbroeck, M., 413
- Tephly, T., *see* Styczynski, P., 80
- Teraoka, K., *see* Morita, K., 112
- Terry, B., *see* Yamanaka, G., 446
- Terry, B. J., Cianci, C. W., and Hagen, M. E. Inhibition of herpes simplex virus type 1 DNA polymerase by [1R(1 α ,1 β ,3 α)]-9-[2,3-Bis(hydroxymethyl)cyclobutyl]guanine, 591
- Thastrup, O., *see* Hughes, A. R., 254
- Thayer, S. A., *see* Werth, J. L., 742
- Thérien, M., *see* Evans, J. F., 22
- Thio, L. L., *see* Zorumski, C. F., 45
- Thomas, B. F., Compton, D. R., Martin, B. R., and Semus, S. F. Modeling the cannabinoid receptor: A three-dimensional quantitative structure-activity analysis, 656
- Thomsen, W. J., *see* Trainer, V. L., 988
- Trainer, V. L., Thomsen, W. J., Catterall, W. A., and Baden, D. G. Photoaffinity labeling of the brevetoxin receptor on sodium channels in rat brain synaptosomes, 988
- Triggle, D. J., *see* Zheng, W., 734
- Trump-Kallmeyer, S., *see* Hibert, M. F., 8
- Tsai, A.-L., *see* Kulmacz, R. J., 833
- Tuomari, A. V., *see* Yamanaka, G., 446
- Tyndale, R. F., Sunahara, R., Inaba, T., Kalow, W., Gonzalez, F. J., Niznik, H. B. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): Potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6, 63
- U**
- Uhl, C., *see* Sill, J. C., 1006

V

- Van Boom, J. H., *see* Noort, D., 316
 Van Der Marel, G. A., *see* Noort, D., 316
 VanDongen, A. M. J., *see* Tagliatela, M., 299
 Van Dyke, R., *see* Sill, J. C., 1006
 Van Rensburg, C. J., *see* Anderson, R., 427
 Vatsis, K. P., *see* Martell, K. J., 218
 Vickers, P. J., *see* Evans, J. F., 22
 Vigé, X., Costa, E., and Wise, B. C. Mechanism of nerve growth factor mRNA regulation by interleukin-1 and basic fibroblast growth factor in primary cultures of rat astrocytes, 186
 Vincent, M. S. and Near, J. A. Purification of a [³H]dihydrotetrabenazine-binding protein from bovine adrenal medulla, 889
 Visser, T. J., *see* Noort, D., 316
 Voitenko, S., Purnyn, S., Omeltchenko, I., Dyadyusha, G. G., Zhorov, B., Brovtina, N., and Skok, V. Effect of (+)-sparteine on nicotinic acetylcholine receptors in the neurons of rat superior cervical ganglion, 180

W

- Wadler, S. and Yang, C.-P. H. Reversal of doxorubicin resistance by hydrophobic, but not hydrophilic, forskolins, 960
 Waelbroeck, M., Tastenoy, M., Camus, J., and Christophe, J. Binding kinetics of quinuclidinyl benzilate and methyl-quinuclidinyl benzilate enantiomers at neuronal (M₁), cardiac (M₂), and pancreatic (M₃) muscarinic receptors, 413
 Waldo, G. L., Morris, A. J., Klapper, D. G., and Harden, T. K. Receptor- and G-protein-regulated 150-kDa avian phospholipase C: Inhibition of enzyme activity by isoenzyme-specific antisera and nonidentity with mammalian phospholipase C isoenzymes established by immunoreactivity and peptide sequence, 480
 Wall, S. C., *see* Rudnick, G., 421
 Wall, S. J., *see* Li, M., 28
 Wall, S. J., Yasuda, R. P., Li, M., and Wolfe, B. B. Development of an antiserum against m3 muscarinic receptors: Distribution of m3 receptors in rat tissues and clonal cell lines, 783
 Walsh, K. B. Activation of a heart chloride current during stimulation of protein kinase C, 342
 Wang, C.-D., Buck, M. A., and Fraser, C. M. Site-directed mutagenesis of α_{2A} -adrenergic receptors: Identification of amino acids involved in ligand binding and receptor activation by agonists, 168
 Wang, H.-L., *see* Raynor, K., 248
 Wang, Y., and Rosenberg, R. L. Ethaverine, a derivative of papaverine, inhibits cardiac L-type calcium channels, 750
 Watts, C. K. W., *see* Handel, M. L., 613
 Weber, W. W., *see* Martell, K. J., 218
 Weinshank, R. L., *see* Zgombick, J. M., 1036
 Wellstein, A., *see* Li, M., 28
 Werth, J. L., Hirning, L. D., and Thayer, S. A. ω -Conotoxin exerts functionally distinct low and high affinity effects in the neuronal cell line NG108-15, 742
 Westbrook, G. L., *see* Legendre, P., 289
 White, G., *see* Lovinger, D. M., 263
 Whiting, P., Schoepfer, R., Lindstrom, J., and Priestley, T. Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts, 463
 Williams, D. E., *see* Lemoine, A., 211
 Williams, H. J., *see* Narasimhan, T. R., 1029
 Williams, K., Hanna, J. L., Molinoff, P. B. Developmental changes in

the sensitivity of the N-methyl-D-aspartate receptor to polyamines, 774

- Willingham, M. C., *see* Lelong, I. H., 490
 Wise, B. C., *see* Vigé, X., 186
 Wolfe, B. B., *see* Li, M., 28
 Wolfe, B. B., *see* Wall, S. J., 783
 Wu, F.-S., Gibbs, T. T., and Farb, D. H. Pregnenolone sulfate: A positive allosteric modulator at the NMDA receptor, 333
 Wyatt, T. A., *see* Cornwell, T. L., 923

X

- Xin, W., *see* Rimland, J., 869

Y

- Yamamoto, K., *see* Schwinn, D. A., 619
 Yamanaka, G., Tuomari, A. V., Hagen, M., McGeever-Rubin, B., Terry, B., Haffey, M., Bisacchi, G. S., and Field, A. K. Selective activity and cellular pharmacology of (1R-1 α , 2 β , 3 α)-9[2,3-bis(hydroxymethyl)cyclobutyl]-guanine in herpesvirus infected cells, 446
 Yang, C.-P. H., *see* Wadler, S., 960
 Yasuda, R. P., *see* Li, M., 28
 Yasuda, R. P., *see* Wall, S. J., 783
 Yoburn, B. C., *see* Franklin, S. O., 515
 Yun, C.-H., *see* Srivastava, P. K., 69
 Yun, C.-H., Shimada, T., and Guengerich, F. P. Purification and characterization of human liver microsomal cytochrome P-450 2A6, 679

Z

- Zamboni, R., *see* Evans, J. F., 22
 Zeng, D., *see* Harrison, J. K., 407
 Zgombick, J. M., Weinshank, R. L., Macchi, M., Schechter, L. E., Branchek, T. A., and Hartig, P. R. Expression and pharmacological characterization of a canine 5-hydroxytryptamine_{1D} receptor subtype, 1036
 Zhang, L., Horowitz, B., and Buxton, I. L. O. Muscarinic receptors in canine colonic circular smooth muscle. I. Coexistence of M₂ and M₃ subtypes, 943
 Zhang, L. and Buxton, I. L. O. Muscarinic receptors in canine colonic circular smooth muscle. II. Signal transduction pathways, 952
 Zheng, W., Rampe, D., and Triggle, D. J. Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca²⁺ channel activator, in cardiac and vascular preparations, 734
 Zhorov, B., *see* Voitenko, S., 180
 Zhu, Y.-S., *see* Franklin, S. O., 515
 Zhu, Z., Hitchcock, M. J. M., and Sommadossi, J. P. Metabolism and DNA interaction of 2',3'-didehydro-2',3'-dideoxythymidine in human bone marrow cells, 838
 Zilberter, Y., Uteshev, V., Sokolova, S., and Khodorov, B. Desensitization of N-methyl-D-aspartate receptors in neurons dissociated from adult rat hippocampus, 337
 Zorumski, C. F., Thio, L. L., and Clifford, D. B. Effects of bromowillardiine and willardiine on non-N-methyl-D-aspartate receptors in postnatal rat hippocampal neurons, 45
 Zukin, R. S., *see* Haring, R., 666
 Zukin, S. R., *see* Haring, R., 666
 Zwiller, J., *see* Honkanen, R. E., 577

SUBJECT INDEX FOR VOLUME 40

A

- Acetaminophen, perturbation of tyrosyl radical, prostaglandin H synthase, 833
- Acetylation, rapid and slow, molecular genetic basis (mouse), 218
- Acetylcholine
 muscarinic receptor-mediated prostacyclin, cGMP synthesis, vascular cells (bovine), 101
 muscarinic receptors, colonic circular smooth muscle (dog), 943, 952
 stimulus-induced, novel receptor site (rat), 16
 three-dimensional models, G-binding protein-coupled receptors, 8
- N*-Acetyl-*p*-benzoquinoneimine, prevention of cytotoxicity, diethyldithiocarbamate, dithiotreitol (rat), 125
- Acquired immunodeficiency syndrome, phosphorylation of anti-HIV nucleosides, inhibitors of IMP dehydrogenase, 118
- Adenosine, inhibition of transport by ethanol, regulation, cAMP-dependent protein kinase, 812
- Adenosine triphosphate
 depletion, phosphofructokinase inactivation by auranofin, neutrophils (human), 427
 regulation of phospholipase C, 5'-nucleotide receptor, airway epithelial cells (human), 648
- Adenylate cyclase
 activation, β -adrenergic agonist binding frequency, 276
 pathways of desensitization, A₁- and A₂-adenosine receptors, DDT, MF-2 cells, 639
 prostaglandin receptors in NIH 3T3 cells, 633
- Adenylyl cyclase
 inhibitory GTP-binding regulatory protein G₁₃, coupling of angiotensin II receptors, hepatocytes (rat), 156
 multiple G_i protein subtypes, single effector mechanism, 707
 sensitization, P₂ purinergic and M5 muscarinic receptor agonists, L cells, 539
 subtypes of brain somatostatin receptors, coupling, multiple effector systems (rat), 248
- Adipocytes, glucose transporter differentiation (human, rat), 383
- Adipose tissue, molecular cloning and expression, β_3 -adrenergic receptor (rat), 895
- Adrenal cortex, cytochrome P-450, 17 α -hydroxylase, spironolactone-mediated destruction (guinea pig), 321
- Adrenal gland
 angiotensin II receptor subtypes (bovine, rat), 401
 chromaffin cells
 clonidine-displacing substance, imidazoline receptors (bovine), 884
 palytoxin, inhibition of tyrosine uptake (bovine), 112
 proenkephalin and tyrosine hydroxylase gene expression, transsynaptic activity, response to reserpine (hamster), 515
- Adrenal medulla
 chromaffin cells, Ca²⁺-dependent catecholamine secretion, trichosporin-B-III (bovine), 790
 purification of dihydrotetrabenazine-binding protein (bovine), 889
 tyrosine hydroxylase gene transcription, nicotine (rat), 193
- Adrenaline, G-binding protein-coupled receptors, three-dimensional models, 8
- Adrenoceptors
 α -1, interaction of subtype-selective antagonists (rat), 523, 531
 α -1C, signal transduction pathways, mammalian tissue heterogeneity, 619
 α -1D, solution-phase library screening, rare clones, 876
 α -2
 multiple G_i protein subtypes, single effector mechanism, 707
 pharmacological characterization (rat), 407
 α -2A, site-directed mutagenesis, 168
 α -2-C10, molecular interaction, fibroblasts (human, rat), 627
 α -2D, bovine pineal gland, 235
 β , agonist binding frequency, adenylate cyclase activation, 276
 β -2, decreased mRNA expression, S49 lymphoma cells, 974
 β -3, molecular cloning and expression (rat), 895
- Affective disorders, inositol monophosphate inhibition, K-76COONa (bovine), 107
- Agonist
 -induced inositol phosphate, inhibition by halothane, vascular smooth muscle cells, 1006
 interactions with M2 and M4 muscarinic receptor subtypes, mediation, cAMP inhibition, 1014
- Agranulocytosis, clozapine-induced, possible role, free radical formation (human), 846
- Airway, epithelial cells, regulation of phospholipase C, 5'-nucleotide receptor (human), 648
- Albumin, -histamine conjugates at histamine H₂ receptors, agonistic activities, HL-60 cells, 271
- Alkylating agents, quinone, mechanisms for modulation, 454
- Alzheimer's disease, novel receptor site, stimulus-induced acetylcholine, dopamine and serotonin (rat), 16
- 3-Amino-1,2,4-benzotriazine 1,4-dioxide, microsomal reduction to a free radical, 440
- Amino acids
 residues involved in dendrotoxin block, voltage-dependent potassium channels (rat), 572
 site-directed mutagenesis, α_{2A} -adrenergic receptors, 168
- γ -Aminobutyric acid, negative modulation of response, extracellular zinc (chick), 766
- α -Aminoisobutyric acid, trichosporin-B-III, catecholamine secretion, adrenal medullary chromaffin cells (bovine), 790
- Anesthetics, frequency and voltage-dependent inhibition, type IIA Na⁺ channels, mammalian cell line (rat), 756
- Angiotensin II
 biochemical analysis of solubilized receptors, neuroblastoma N1E-115 cells, 717
 characterization of binding sites, R3T3 cells, 360
- Antiarhythmic drugs, frequency and voltage-dependent inhibition, type IIA Na⁺ channels, mammalian cell line (rat), 756
- Anticonvulsant drugs, frequency and voltage-dependent inhibition, type IIA Na⁺ channels, mammalian cell line (rat), 756
- Anticyclooxygenase agents, perturbation of tyrosyl radical, prostaglandin H synthase, 833
- Antifolates, sensitivity and natural resistance, methylcholanthrene-induced sarcoma (rat), 854
- Antigen, -induced responses in RBL-2H3 cells, down-regulation of GTP-binding protein, dexamethasone, 473
- Antimalarial agents, reversed siderophores, 584
- Antimitotic agents, 2-styrylquinazolin-4(3H)-one derivatives, interaction of tubulin, 827
- Antioxidants, nifedipine and nimodipine (rat), 435
- Antipeptide antibodies, localization of *N*-(4-azido-3-[¹²⁵I]iodophenethyl)sipiperone binding, carboxyl-terminal portion, D₂ dopamine receptor, 712
- Antiserum, development of, m3 muscarinic receptors (rat), 783
- Arachidonic acid, inhibition of acylation by tetrahydrocannabinol, phospholipids and triacylglycerols, cerebral cortex (guinea pig), 547
- Aryl hydrocarbon hydroxylase, cytochrome P4501A1 induction, non-responders, Ah receptor (mouse), 818
- Aryl sulfotransferase IV, hepatic (rat), 36

Ascorbic acid, clozapine-induced agranulocytosis, possible role, free radical formation (human), 846
 Aspirin, perturbation of tyrosyl radical, prostaglandin H synthase, 833
 Assays, fluorometric, DNA topoisomerases, topoisomerase-targeted drugs, 495
 Astrocytes, nerve growth factor mRNA, interleukin 1, basic fibroblast growth factor (rat), 186
 Atrial natriuretic factor, R_1 receptor subtype, heterogeneity, pharmacological evidence, 915
 Auranofin, inactivation of phosphofructokinase, neutrophils (human), 427
 Aurothiomalate, other metal ions and, inhibition of DNA binding, nuclear receptor transcription factor, 613
 Autoradiography, opioid binding sites in kidney (guinea pig, rat), 93
 Avermectin, -sensitive chloride currents, *Caenorhabditis elegans* RNA, *Xenopus* oocytes, 368
N-(4-Azido-3-[125 I]iodophenethyl)piperone, localization by antipeptide antibodies, carboxyl-terminal portion, D_2 dopamine receptor, 712

B

Bilirubin
 -degrading system, cytochrome P450IA1, liver microsomes (rat), 686
 dimethyl ester, bile, glutathione conjugates (rat), 597
 [1*R*(1 α ,2 β ,3 α)]-9-[2,3-Bis(hydroxymethyl)cyclobutyl]guanine inhibition of herpes simplex virus type 1 DNA polymerase, 591
 metabolism by herpesvirus, 446
 Bone marrow, DNA interaction, 2',3'-didehydro-2',3'-dideoxythymidine (human), 838
 Botulinum C2 toxin, inhibition of cytoskeletal rearrangement, ligand-evoked lipid mediator generation, neutrophils (human), 563
 Bradykinin, role of inositol (1,4,5)trisphosphate, EGF-induced Ca^{2+} signaling, A431 cells, 254
 Brain
 cloning and expression, A_1 adenosine receptor (rat), 1
 distribution of m2 muscarinic receptors (rat), 28
 frontal cortex and spinal cord, GABA $_A$ receptor complexes, steroid modulation (rat), 995
 interaction of subtype-selective antagonists, α_1 -adrenergic receptor-mediated second messenger responses (rat), 523
 major nicotinic acetylcholine receptor subtype, fibroblasts (mouse), 463
 novel receptor site, stimulus-induced acetylcholine, dopamine and serotonin (rat), 16
 postnatal hippocampal neurons, bromowillardine and willardine, non-NMDA receptors (rat), 45
 somatostatin receptor subtypes, coupling, multiple cellular effector systems (rat), 248
 superior cervical ganglion, sparteine effect, nicotinic acetylcholine receptors (rat), 180
 synaptosomes, photoaffinity labeling, brevetoxin receptor (rat), 988
 tissue-dependent association, muscarinic acetylcholine receptors, G-proteins, 347
 Breast cancer, 17 β -estradiol-induced glucose metabolism, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 1029
 Bromowillardine, willardine and, non-*N*-methyl-D-aspartate receptors, postnatal hippocampal neurons (rat), 45

C

Caenorhabditis elegans
 RNA in *Xenopus* oocytes, avermectin-sensitive chloride current, 368
 solubilization and characterization, high affinity ivermectin binding site, 326
 Calcium
 -dependent catecholamine secretion, trichosporin-B-III, adrenal medullary chromaffin cells (bovine), 790
 epidermal growth factor-induced signaling, role of inositol (1,4,

5)trisphosphate, A431 cells, 254
 histamine-albumin conjugates, agonistic activities, histamine H_2 receptors, 271
 signaling in vascular smooth muscle cells, agonist-induced inositol phosphate, inhibition by halothane, 1006
 Calcium channels
 cardiac L-type, inhibition by ethaverine (pig), 750
 novel activator FPL 64176 (rat), 734
 subtypes of brain somatostatin receptors, coupling, multiple effector systems (rat), 248
 Calcium current, inhibition, μ -opioid receptor, SH-SY5Y cells, 1000
 Cannabinoid, receptor, modeling of, 656
 Cannabinoid hydroxylase, hepatic, cytochrome P-450IIC subfamily (mouse), 228
 Carbamazepine, frequency and voltage-dependent inhibition, type IIA Na^+ channels, mammalian cell line (rat), 756
 Carbonyl reductase, genomic sequence and expression, daunorubicin reductase activity (human), 502
 2 β -[3H] Carboxymethoxy-3 β -(4-fluorophenyl)tropane, binding to serotonin transporter, 421
 Catecholamines
 adrenal chromaffin cells, clonidine-displacing substance, imidazoline receptors (bovine), 884
 Ca^{2+} -dependent secretion, trichosporin-B-III, adrenal medullary chromaffin cells (bovine), 790
 palytoxin, inhibition of tyrosine uptake (bovine), 112
 Cerebral cortex, inhibition of arachidonic acid acylation, tetrahydrocannabinol (guinea pig), 547
 Charybdotoxin, glyburide-sensitive K^+ channels, hippocampal neurons (rat), 308
 Chlordecone, *see* Kepone
 Chloride current
 avermectin-sensitive, *Caenorhabditis elegans* RNA, *Xenopus* oocytes, 368
 heart, activation during stimulation, protein kinase C (guinea pig), 342
 CHO-K1 cells, functional responses, cloned muscarinic receptors, 242
 Chromaffin cells
 adrenal
 clonidine-displacing substance, imidazoline receptors (bovine), 884
 palytoxin, inhibition of tyrosine uptake (bovine), 112
 adrenal medullary, Ca^{2+} -dependent catecholamine secretion, trichosporin-B-III (bovine), 790
 Clonidine, -displacing substance, imidazoline receptors, catecholamines in adrenal chromaffin cells (bovine), 884
 Clozapine, -induced agranulocytosis, possible role, free radical formation (human), 846
 Cocaine
 binding of analog 2 β -[3H]-carboxymethoxy-3 β -(4-fluorophenyl)tropane, serotonin transporter, 421
 neuronal cytochrome P450IID1, 63
 ω -Conotoxin, low and high affinity effects, neuronal cell line NG108-15, 742
 COS-7 cells, α_{1C} -adrenergic receptor, signal transduction pathways, 619
 Cromakalim, glyburide-sensitive K^+ channels, hippocampal neurons (rat), 308
 Cyanobacteria, nodularin, inhibitor of type 1 and type 2A protein phosphatases (rabbit), 577
 Cyclic AMP
 -dependent protein kinase, regulation, inhibition of adenosine transport by ethanol, 812
 glucocorticoid receptor activation, up-regulation, adenosine A_1 receptors, 149
 inhibition, interactions of agonists, M2 and M4 muscarinic receptor subtypes, 1014
 Cyclic GMP
 -dependent protein kinase, regulation of sarcoplasmic reticulum, vascular smooth muscle cells, 923

Cyclic GMP—continued

muscarinic receptor-mediated synthesis, prostacyclin, vascular cells (bovine), 101

Cytochalasin B, glucose transporter differentiation (human, rat), 383

Cytochrome P-450

adrenal, 17 α -hydroxylase, spironolactone-mediated destruction (guinea pig), 321

2E1 and 2E2, differences, developmental expression (rabbit), 58

Cytochrome P-450 2A6, liver microsomal, purification, characterization (human), 679

Cytochrome P-450IA, gene subfamily, expression and molecular regulation, pyridine (rat), 52

Cytochrome P-450IA1

inducible bilirubin-degrading system, liver microsomes (rat), 686

induction, nonresponders, Ah receptor (mouse), 818

Cytochrome P-450IIC, subfamily, major hepatic cannabinoid hydroxylase (mouse), 228

Cytochrome P-450IID1, debrisoquine/sparteine-type, cocaine activity, human hepatic P450 gene *CYP2D6*, 63

Cytochrome P-450IID6, -catalyzed hydroxylation, enantiomer/enantiomer interaction, propafenone (human), 135

Cytochrome P-450 IIIA, -dependent metabolism of digitoxin, species differences, toxicity in mammals, 859

Cytochrome P-450e, selective induction by kepone, hepatocytes (rat), 203

Cytoskeleton, inhibition of rearrangement by botulinum C2 toxin, ligand-evoked lipid mediator generation, neutrophils (human), 563

D

Daunorubicin, reductase activity, genomic sequence and expression, carbonyl reductase gene (human), 502

DDT₁ MF-2 cells, pathways of desensitization, A₁- and A₂-adenosine receptors, 639

Debrisoquine, -sparteine-type neuronal cytochrome P450IID1, cocaine activity, human hepatic P450 gene *CYP2D6*, 63

Dendrotoxin, block of voltage-dependent potassium channels, amino acid residues (rat), 572

2'-Deoxy-6-thioguanosine 5'-triphosphate, substrate for purified human DNA polymerases, calf thymus terminal deoxynucleotidyltransferase, 508

Desferal, reversed siderophores as antimalarial agents, 584

Dexamethasone

down-regulation of GTP-binding protein, antigen-induced responses, RBL-2H3 cells, 473

glucocorticosteroid receptor activation, up-regulation, adenosine A₁ receptors, 149

2',3'-Didehydro-2',3'-dideoxythymidine, DNA interaction, bone marrow cells (human), 838

2',3'-Dideoxyadenosine, 2',3'-dideoxyinosine and, phosphorylation, inhibitors of IMP dehydrogenase, 118

Diethyldithiocarbamate, dithiothreitol and, prevention, *N*-acetyl-*p*-benzoquinoneimine cytotoxicity (rat), 125

Digitoxin, cytochrome P450 IIIA-dependent metabolism, species differences, toxicity in mammals, 859

Dihydratetrabenazine, -binding protein, purification, adrenal medulla (bovine), 889

Dimaprit, theoretical studies, histamine H₂ receptor, 980

Dioxin, agonists, ultraviolet photoproducts, tryptophan (guinea pig), 674

Dipyridamole, glucose transporter differentiation (human, rat), 383

DNA

inhibition of binding and transcriptional activity, nuclear receptor transcription factor, aurothiomalate and other metal ions, 613

interaction of 2',3'-didehydro-2',3'-dideoxythymidine, bone marrow cells (human), 838

metal- and photo-induced cleavage, podophyllotoxin, etoposide and related compounds, 965

molecular genetic basis, rapid and slow acetylation (mouse), 218

oligonucleotide models, molecular mechanics and dynamics, 1023

trifluoroacetylated liver protein adducts, halothane metabolism (rat), 390

DNA, complementary

α_{1D} -adrenergic receptor, solution-phase library screening, rare clones, 876

neuropeptide Y receptor, 869

DNA polymerases

2'-deoxy-6-thioguanosine 5'-triphosphate as substrate, calf thymus terminal deoxynucleotidyltransferase, 508

herpes simplex virus type 1, [1R(1 α ,2 β ,3 α)]-9-[2,3-bis(hydroxymethyl)cyclobutyl] guanine, 591

DNA topoisomerases

eukaryotic, inhibition of activities, indolodquinolinedione derivatives, 699

topoisomerase-targeted drugs and, fluorometric assays, 495

Dopamine

G-binding protein-coupled receptors, three-dimensional models, 8

stimulus-induced, novel receptor site (rat), 16

Doxorubicin, reversal of resistance, hydrophilic forskolins (mouse), 960

Dynemicin-A, molecular mechanics and dynamics, intercalation, oligonucleotide models of DNA, 1023

E

Electrophysiology, novel Ca²⁺ channel activator FPL 64176 (rat), 734

Endothelial cells, cultured vascular cells, muscarinic receptor-mediated prostacyclin, cGMP synthesis (bovine), 101

Epithelial cells, airway, regulation of phospholipase C, 5'-nucleotide receptor (human), 648

Erythrocytes

glucose transporter differentiation (human, rat), 383

reversed siderophores as antimalarial agents, 584

17 β -Estradiol, -induced glucose metabolism, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, breast cancer cells, 1029

Estrogen, receptor stereochemistry (mouse), 806

Ethanol

inhibition of adenosine transport, regulation, cAMP-dependent protein kinase, 812

potentiation of 5-HT₃ receptor-mediated ion current, neuroblastoma cells, mammalian neurons, 263

Ethaverine, inhibition of cardiac L-type calcium channels (pig), 750

Etoposide, metal- and photo-induced cleavage of DNA, 965

F

Fenamate, perturbation of tyrosyl radical, prostaglandin H synthase, 833

Fibroblast growth factor, basic, interleukin 1 and, nerve growth factor mRNA (rat), 186

Fibroblasts

major nicotinic acetylcholine receptor subtype (mouse), 463

rat-1, molecular interaction, human α_2 -C10-adrenergic receptor, 627

Flavin

-containing monooxygenases

hormone regulation (rat), 211

multiple forms, liver and lung (rabbit), 692

Fluorescence, anti-idiotypic antibodies, stereospecificity of opiate receptors, NG108-15 cells, 354

Flurbiprofen, perturbation of tyrosyl radical, prostaglandin H synthase, 833

Forebrain, membranes, high efficiency reconstitution, phencyclidine/MK-801 receptor binding (rat), 666

Forskolin

glucose transporter differentiation (human, rat), 383

hydrophilic, reversal, doxorubicin resistance (mouse), 960

FPL 64176, novel Ca²⁺ channel activator (rat), 734

Free radical

formation, clozapine-induced agranulocytosis (human), 846

microsomal reduction, 3-amino-1,2,4-benzotriazine 1,4-dioxide, 440

G

Gene

- carbonyl reductase, genomic sequence, daunorubicin reductase activity (human), 502
- CYP2C18 mRNA, polymerase chain reaction-directed identification, 375
- CYP2D6, neuronal cytochrome P450IID1, 63
- expression and pharmacological characterization, 5-HT_{1D} receptor subtype (dog), 1036

Glucose

- 17 β -estradiol-induced metabolism, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, breast cancer cells, 1029
- transporters, differentiation (human, rat), 383

Glutathione, conjugates of dimethyl ester, bilirubin, bile (rat), 597

Glyburide, -sensitive K⁺ channels, hippocampal neurons (rat), 308

G-protein

- cloning and expression, A₁ adenosine receptor, brain (rat), 1
- coupled receptors, three-dimensional models, 8
- glucocorticoid receptor activation, up-regulation, adenosine A₁ receptors, 149
- molecular interaction of human α_2 -C10-adrenergic receptor, rat-1 fibroblasts, 627
- opioid binding sites in kidney (guinea pig, rat), 93
- regulation by 150-kDa phospholipase C, 480
- solubilization, form of P_{2Y}-purinergic receptor (turkey), 85

G_i protein, multiple subtypes, single effector mechanism, 707

Growth factors, epidermal, inositol (1,4,5)trisphosphate, Ca²⁺, 254

Growth hormone, regulation of microsomal flavin-containing monooxygenase (rat), 211

GTP-binding proteins

- β -adrenergic agonist binding frequency, adenylate cyclase activation, 276
- down-regulation by dexamethasone, antigen-induced responses, RBL-2H3 cells, 473

G₁₃, coupling of angiotensin II receptors, adenylyl cyclase (rat), 156

muscarinic receptors, colonic circular smooth muscle (dog), 952

subtypes of brain somatostatin receptors, coupling, multiple effector systems (rat), 248

subtype-specific antibodies

muscarinic cholinergic receptors (chick), 908

muscarinic cholinergic receptors, cardiac membranes, 900

Guanine nucleotide-regulatory proteins, tissue-dependent association, muscarinic acetylcholine receptors, 347

N_a-Guanylhistamine, theoretical studies, histamine H₂ receptor, 980

H

Halothane

inhibition of agonist-induced inositol phosphate, Ca²⁺ signaling, vascular smooth muscle cells, 1006

metabolism, molecular mimicry, TFA-adducts (rat), 390

Harmol, selective inhibition of glucuronidation, 2,2,2-triphenethyl-UDP (rat), 316

Heart

activation of chloride current, stimulation, protein kinase C (guinea pig), 342

homogenate and model system, illuminated and nonilluminated nifedipine and nimodipine (rat), 435

L-type calcium channels, inhibition by ethaverine (pig), 750

membranes, subtype-specific antibodies, muscarinic cholinergic receptors, 900

muscarinic cholinergic receptors, subtype-specific antibodies (chick), 908

muscarinic receptors, kinetics of QNB enantiomers, 413

novel Ca²⁺ channel activator FPL 64176 (rat), 734

tissue-dependent association, muscarinic acetylcholine receptors, G-proteins, 347

HeLa cells, α_{1C} -adrenergic receptor, signal transduction pathways, 619

Hepatocytes

inhibitory GTP-binding regulatory protein G₁₃, coupling of angiotensin II receptors, adenylyl cyclase (rat), 156

selective induction of cytochrome P450e, kepone (rat), 203

selective inhibition of glucuronidation, 2,2,2-triphenethyl-UDP (rat), 316

Herpes simplex virus

inhibition by [1*R*(1 α ,2 β ,3 α)]-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine

type 1 DNA polymerase, 591

metabolism, 446

Hippocampus, desensitization of NMDA receptors in neurons (rat), 337

Histamine

-albumin conjugates at histamine H₂ receptors, agonistic activities, HL-60 cells, 271

H₂ receptor model, theoretical studies, 980

HL-60 cells, histamine-albumin conjugates, agonistic activities, histamine H₂ receptors, 271

Human immunodeficiency virus, phosphorylation of anti-HIV nucleosides, inhibitors of IMP dehydrogenase, 118

Hydrocarbons, aromatic, Ah receptor, cytochrome P4501A1 induction, nonresponders (mouse), 818

N-Hydroxy-2-acetylaminofluorene, selective inhibition of glucuronidation, 2,2,2-triphenethyl-UDP (rat), 316

4-Hydroxybiphenyl UDP-glucuronosyltransferase, phenobarbital-inducible, purification and properties (rat), 80

17 α -Hydroxylase, spironolactone-mediated destruction, adrenal cytochrome P-450 (guinea pig), 321

I

Ibuprofen, perturbation of tyrosyl radical, prostaglandin H synthase, 833

Ifenprodil, block of N-methyl-D-aspartate receptors, two-component mechanism (rat), 289

IMP dehydrogenase, inhibitors, phosphorylation of anti-HIV nucleosides, 118

Indoloquinolinedione derivatives, inhibition, eukaryotic DNA topoisomerase I and II, 699

Indomethacin, perturbation of tyrosyl radical, prostaglandin H synthase, 833

Inositol (1,4,5)trisphosphate, epidermal growth factor-induced Ca²⁺ signaling, A431 cells, 254

Inositol monophosphate, noncompetitive inhibition, K-76 monocarboxylic acid (bovine), 107

Inositol phosphate, agonist-induced, inhibition by halothane, vascular smooth muscle cells, 1006

Interleukin 1, basic fibroblast growth factor and, nerve growth factor mRNA, astrocytes (rat), 186

Ion channels

glyburide-sensitive K⁺ channels, hippocampal neurons (rat), 308

N-methyl-D-aspartate receptors, block by ifenprodil, two-component mechanism (rat), 289

Ion current, 5-HT₃ receptor-mediated, ethanol potentiation, neuroblastoma cells, 263

Iron(III), reversed siderophores as antimalarial agents, 584

Isobutylmethylxanthine, glucose transporter differentiation (human, rat), 383

Ivermectin, high affinity binding site, solubilization and characterization, *Caenorhabditis elegans*, 326

K

Kainate, bromowillardine and willardine, non-NMDA receptors, postnatal hippocampal neurons (rat), 45

K-76COONa, monocarboxylic acid, inositol monophosphatase inhibition (bovine), 107

Kepone, selective induction of cytochrome P450e, hepatocytes (rat), 203

L

- L cells, sensitization of adenylyl cyclase, P₂ purinergic and M5 muscarinic receptor agonists, 539
- Leukotriene, synthesis inhibitors, quinoline class, 5-lipoxygenase-activating protein (rat, human), 22
- Lidocaine, frequency and voltage-dependent inhibition, type IIA Na⁺ channels, mammalian cell line (rat), 756
- Ligands
 estrogen receptor stereochemistry (mouse), 806
 -evoked lipid mediator generation, inhibition of cytoskeletal rearrangement, botulinum C2 toxin in neutrophils (human), 563
 high affinity retinoic acid receptor α or β - γ , 556
 site-directed mutagenesis, α_{2A} -adrenergic receptors, 168
- Lipids, ligand-evoked mediator generation, botulinum C2 toxin, inhibition of cytoskeletal rearrangement (human), 563
- 5-Lipoxygenase, -activating protein, target of quinoline class, leukotriene synthesis inhibitors (rat, human), 22
- Lithium, K-76COONa, inositol monophosphatase inhibition (bovine), 107
- Liver
 cannabinoid hydroxylase, cytochrome P-450IIC subfamily (mouse), 228
 flavin-containing monooxygenases (rabbit), 692
 glucose transporter differentiation (human, rat), 383
 hepatic aryl sulfotransferase IV (rat), 36
 phenobarbital-inducible 4-hydroxybiphenyl UDP-glucuronosyltransferase, purification and properties (rat), 80
 trifluoroacetylated adducts, halothane metabolism (rat), 390
- Liver microsomes
 cytochrome P-450 2A6, purification, characterization (human), 679
 enantiomer/enantiomer interaction, cytochrome P450IID6-catalyzed hydroxylation, propafenone (human), 135
 inducible bilirubin-degrading system, cytochrome P450IA1 (rat), 686
 tolbutamide hydroxylase, (S)-mephénytoin 4'-hydroxylase cytochrome P-450 enzymes, 69
- Lung, flavin-containing monooxygenases (rabbit), 692
- Lymphoma, S49 cells, decreased β_2 -adrenergic receptor mRNA expression, 974

M

- Magnesium, K-76COONa, inositol monophosphate inhibition (bovine), 107
- Marijuana, major hepatic cannabinoid hydroxylase, cytochrome P-450IIC subfamily (mouse), 228
- (S)-Mephénytoin 4'-hydroxylase cytochrome P-450 enzymes, separation, human liver microsomal tolbutamide hydroxylase, 69
- Metal, -induced DNA cleavage, podophyllotoxin, etoposide and related compounds, 965
- Metal ions, aurothiomalate, inhibition of DNA binding, nuclear receptor transcription factor, 613
- N-Methyl-D-aspartate, non-NMDA receptors, bromowillardine and willardine, postnatal hippocampal neurons (rat), 45
- Methylcholanthrene, -induced sarcoma, sensitivity and natural resistance, antifolates (rat), 854
- Microsomes, reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide, free radical, 440
- MK-801
 receptor binding, phencyclidine, forebrain membranes (rat), 666
 sensitivity of NMDA receptor to polyamines, developmental changes (rat), 774
- Monooxygenase
 cytochromes P-450 2E1 and 2E2, differences, developmental expression (rabbit), 58
 flavin-containing, multiple forms, liver and lung (rabbit), 692
 microsomal flavin-containing, hormone regulation (rat), 211
- Morphine, μ -opioid receptor, inhibition of calcium current, SH-SY5Y cells, 1000

- Multidrug resistance, fluorescent verapamil derivative, monitoring of activity, 490
- Muscle, smooth
 colonic circular, muscarinic receptors (dog), 943, 952
 glucocorticoid receptor activation, up-regulation, adenosine A₁ receptors, 149
- vascular
 agonist-induced inositol phosphate, inhibition by halothane, 1006
 regulation of sarcoplasmic reticulum, cGMP-dependent protein kinase, 923
- Mutagenesis, site-directed, α_{2A} -adrenergic receptors, 168
- Mycophenolic acid, inhibitors of IMP dehydrogenase, phosphorylation, anti-HIV nucleosides, 118

N

- NADPH-cytochrome P450 reductase, cytochromes P-450 2E1 and 2E2, differences, developmental expression (rabbit), 58
- α -Naphthoflavone, antagonist of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, formation of inactive complex, Ah receptor (mouse), 607
- Naproxen, perturbation of tyrosyl radical, prostaglandin H synthase, 833
- Neonate, cytochromes P-450 2E1 and 2E2, differences, developmental expression (rabbit), 58
- Nerve growth factor, mRNA regulation, interleukin 1 and basic fibroblast growth factor, astrocytes (rat), 186
- Neuroblastoma
 5-HT₃ receptor-mediated ion current, ethanol potentiation, 263
 solubilized angiotensin II receptors, biochemical analysis, 717
- Neuronal cells, NG108-15, ω -conotoxin, low and high affinity effects, 742
- Neurons
 desensitization of NMDA receptors, hippocampus (rat), 337
 hippocampal, glyburide-sensitive K⁺ channels (rat), 308
 mammalian, 5-HT₃ receptor-mediated ion current, ethanol potentiation, 263
 N-methyl-D-aspartate receptors, block by ifenprodil, two-component mechanism (rat), 289
 postnatal hippocampal, bromowillardine and willardine, non-NMDA receptors (rat), 45
 subtypes of brain somatostatin receptors, coupling, multiple effector systems (rat), 248
 superior cervical ganglion, sparteine effect, nicotinic acetylcholine receptors (rat), 180
- Neuropeptide Y, receptor cDNA, sequence and expression, 869
- Neurotransmitter
 G-binding protein-coupled receptors, three-dimensional models, 8
 novel receptor site, stimulus-induced acetylcholine, dopamine and serotonin (rat), 16
- Neutrophils
 inactivation of phosphofructokinase, auranofin (human), 427
 inhibition of cytoskeletal rearrangement, botulinum C2 toxin, ligand-evoked mediator generation (human), 563
- NG108-15 cells, stereospecificity of opiate receptors, 354
- Nicotine, tyrosine hydroxylase gene transcription, adrenal medulla (rat), 193
- Nifedipine, illuminated and nonilluminated, heart homogenate and model system (rat), 435
- Niguldipine, interaction of subtype-selective antagonists, α_1 -adrenergic receptor binding sites (rat), 531
- NIH 3T3 cells, prostaglandin receptors, 633
- Nimodipine, illuminated and nonilluminated, heart homogenate and model system (rat), 435
- Nodularin, inhibitor of type 1 and type 2A protein phosphatases (rabbit), 577
- Nonsteroidal anti-inflammatory agents, perturbation of tyrosyl radical, prostaglandin H synthase, 833
- Nuclear magnetic resonance spectroscopy, 17 β -estradiol-induced glu-

cose metabolism, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, breast cancer, 1029

Nuclear receptor transcription factor, inhibition of DNA binding, transcriptional activity, aurothiomalate and other metal ions, 613
Nucleosides, anti-HIV, phosphorylation, inhibitors of IMP dehydrogenase, 118

O

Oligonucleotide, models of DNA, molecular mechanics and dynamics, dynemicin-A, 1023
Oocytes, *Xenopus*, *Caenorhabditis elegans* RNA, avermectin-sensitive chloride current, 368
Opioids, binding sites in kidney (guinea pig, rat), 93

P

Palytoxin, inhibition of tyrosine uptake, adrenal chromaffin cells (bovine), 112
Pancreas, muscarinic receptors, kinetics of QNB enantiomers, 413
Pancreatoma, different modes of regulation for receptors, phospholipase C (rat), 727
Papaverine, derivative ethaverine, inhibition, cardiac L-type calcium channels (pig), 750
Pertussis toxin
 inhibitory GTP-binding regulatory protein G₁₃, coupling of angiotensin II receptors, adenylyl cyclase (rat), 156
 -sensitive guanine nucleotide-binding proteins, human α_2 -C10-adrenergic receptor, rat-1 fibroblasts, 627
Phencyclidine, MK-801 receptor binding, high efficiency reconstitution, forebrain membranes (rat), 666
Phenobarbital, -inducible 4-hydroxybiphenyl UDP-glucuronosyltransferase, purification and properties (rat), 80
Phenothiazine, structure-activity relationships, inhibition of protein kinase C, 798
Phenytoin, frequency and voltage-dependent inhibition, type IIA Na⁺ channels, mammalian cell line (rat), 756
Phosphofructokinase, inactivation by auranofin, neutrophils (human), 427
Phospholipase C
 150-kDa, receptor and G-protein regulation, 480
 prostaglandin receptors in NIH 3T3 cells, 633
 receptor activation, different modes of regulation, pancreatoma cell line (rat), 727
 regulation by UTP and ATP, common extracellular 5'-nucleotide receptor, airway epithelial cells (human), 648
 solubilization of guanine nucleotide-sensitive form, P_{2U}-purinergic receptor (turkey), 85
Phospholipids, inhibition of arachidonic acid acylation, tetrahydrocannabinol, cerebral cortex (guinea pig), 547
Photoaffinity, labeling of brevetoxin receptor, sodium channels, brain synaptosomes (rat), 988
Pineal gland, bovine, α_{2D} -adrenergic receptors, 235
Podophyllotoxin, metal- and photo-induced cleavage of DNA, 965
Polyamines, sensitivity of NMDA receptor, developmental changes (rat), 774
Polymerase chain reaction, -directed identification, cloning and quantification, human CYP2C18 mRNA, 375
Polypeptide
 halothane metabolism (rat), 390
 toxins, block of potassium channels, venom (scorpion), 932
Potassium channel
 block, polypeptide toxins, venom (scorpion), 932
 patterns of internal and external tetraethylammonium block, 299
 subtypes of brain somatostatin receptors, coupling, multiple effector systems (rat), 248
 voltage-dependent, dendrotoxin block, amino acid residues (rat), 572
Pregnenolone sulfate, positive allosteric modulator, *N*-methyl-D-aspartate receptor (chick), 333

Proenkephalin, tyrosine hydroxylase gene expression and, response to reserpine, adrenal (hamster), 515
Propafenone, enantiomer/enantiomer interaction, cytochrome P450IID6-catalyzed hydroxylation (human), 135
Prostacyclin, muscarinic receptor-mediated synthesis, vascular cells (bovine), 101
Prostaglandin H synthase, perturbation of tyrosyl radical, probe, anticyclooxygenase agents, 833
Protein kinase
 cAMP-dependent, regulation, inhibition of adenosine transport by ethanol, 812
 cGMP-dependent, regulation of sarcoplasmic reticulum, vascular smooth muscle cells, 923
Protein kinase C
 inhibition, structure-activity relationships, phenothiazines, 798
 stimulation, activation of heart chloride current (guinea pig), 342
Protein phosphatases, type 1 and type 2A, cyanobacterial nodularin (rabbit), 577
Pyridine, expression and molecular regulation, cytochrome P450IA gene subfamily (rat), 52

Q

Quinoline, class of leukotriene synthesis inhibitors, 5-lipoxygenase-activating protein (rat, human), 22
Quinone, alkylating agents, mechanisms for modulation, 454
Quinuclidinyl benzilate, methylquinuclidinyl benzilate enantiomers and, cardiac and pancreatic muscarinic receptors, 413

R

Radioligands, opioid binding sites in kidney (guinea pig, rat), 93
RBL-2H3 cells, GTP-binding protein, down-regulation by dexamethasone, antigen-induced responses, 473
Receptors
 adenosine A₁, cloning and expression, brain (rat), 1
 adenosine A₁ and A₂, pathways of desensitization, DDT₁ MF-2 cells, 639
 adrenergic, *see* Adrenoceptors
 Ah
 α -naphthoflavone, antagonist of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (mouse), 607
 "nonresponse" for cytochrome P450IA1 induction (mouse), 818
 angiotensin II
 inhibitory GTP-binding regulatory protein G₁₃, adenylyl cyclase (rat), 156
 neuroblastoma N1E-115 cells, biochemical analysis, 717
 subtypes and biological responses, adrenal cortex and medulla (bovine, rat), 401
 atrial natriuretic factor-R₁, heterogeneity, pharmacological evidence, 915
 brevetoxin, photoaffinity labeling, brain synaptosomes (rat), 988
 cannabinoid, modeling of, 656
 dopamine D₂, antipeptide antibodies, *N*-(4-azido-3-[¹²⁵I]iodophenethyl)piperone binding, 712
 estrogen, stereochemistry (mouse), 806
 GABA, negative modulation of response, extracellular zinc (chick), 766
 GABA_A, steroid modulation, frontal cortex and spinal cord (rat), 995
 glucocorticoid, up-regulation of adenosine A₁ receptors, smooth muscle cells, 149
 histamine H₂, theoretical studies, 980
 5-HT_{1D}, expression, pharmacological characterization (dog), 1036
 5-HT₃, ethanol potentiation of ion current, neuroblastoma cells, 263
 imidazoline, clonidine-displacing substance, catecholamines in adrenal chromaffin cells (bovine), 884
 N-methyl-D-aspartate
 block by ifenprodil, two-component mechanism (rat), 289
 desensitization in neurons, hippocampus (rat), 337

Receptors—continued

- pregnenolone, positive allosteric modulator (chick), 333
- sensitivity to polyamines, developmental changes (rat), 774
- muscarinic
 - clones, functional responses, 242
 - colonic circular smooth muscle (dog), 943, 952
 - immunological detection of proteins, peripheral tissues (rabbit), 459
 - kinetics of QNB enantiomers, 413
 - prostacyclin and cGMP synthesis, vascular cells (bovine), 101
 - muscarinic acetylcholine, tissue-dependent association, guanine nucleotide-binding regulatory proteins, 347
- muscarinic cholinergic
 - subtype-specific, cardiac membranes, 900
 - subtype-specific antibodies (chick), 908
- muscarinic m2, distribution in brain (rat), 28
- muscarinic M2 and M4, interactions of agonists, mediation of cAMP inhibition, 1014
- muscarinic m3, development of antiserum (rat), 783
- neuropeptide Y, cDNA, sequence and expression, 869
- nicotinic acetylcholine
 - major brain subtype, fibroblasts (mouse), 463
 - neurons, superior cervical ganglion (rat), 180
- non-NMDA, bromowillardine and willardine, postnatal hippocampal neurons (rat), 45
- novel site, acetylcholine, dopamine and serotonin (rat), 16
- 5'-nucleotide, regulation of phospholipase C, airway epithelial cells (human), 648
- opiate, stereospecificity, NG108-15 cells, 354
- opioid *mu*, inhibition of calcium current, SH-SY5Y cells, 1000
- phencyclidine/MK-801, high efficiency reconstitution, forebrain membranes (rat), 666
- phospholipase C, different modes of regulation, pancreatoma cell line (rat), 727
- prostaglandin, NIH 3T3 cells, adenylate cyclase and phospholipase C, 633
- purinergic P_{2Y}, solubilization, guanine nucleotide-sensitive form (turkey), 85
- purinergic P₂ and muscarinic M5, agonists, sensitization of adenylyl cyclase, 539
- retinoic acid, α or β - γ ligands, 556
- serotonin HT_{1D}-type, primary structure, functional characterization (human), 143
- somatostatin, coupling to multiple cellular effector systems, brain (rat), 248
- Reserpine, transsynaptic activity, proenkephalin and tyrosine hydroxylase gene expression, adrenal (hamster), 515
- Retinoic acid, high affinity retinoic acid receptor α or β - γ ligands, 556
- Ribavirin, inhibitors of IMP dehydrogenase, phosphorylation, anti-HIV nucleosides, 118
- RNA, *Caenorhabditis elegans*, *Xenopus* oocytes, avermectin-sensitive chloride current, 368
- RNA, messenger
 - decreased β_2 -adrenergic receptor, S49 lymphoma cells, 974
 - human CYP2C18, polymerase chain reaction-directed identification, 375
 - nerve growth factor, interleukin 1 and basic fibroblast growth factor, astrocytes (rat), 186
- R3T3 cells, characterization of angiotensin II binding sites, 360
- S**
- Sarcoma, methylcholanthrene-induced, sensitivity and natural resistance, antifolates (rat), 854
- Sarcoplasmic reticulum, regulation of protein phosphorylation, cGMP-dependent protein kinase, vascular smooth cells, 923
- Serotonin
 - G-binding protein-coupled receptors, three-dimensional models, 8
 - 5-HT_{1D} receptor subtype, expression, pharmacological characterization (dog), 1036
- 5-HT₃ receptor-mediated ion current, ethanol potentiation, neuroblastoma cells and mammalian neurons, 263
- stimulus-induced, novel receptor site (rat), 16
- transporter, binding of cocaine analog, 421
- SH-SY5Y cells, inhibition of calcium current, μ -opioid receptor, 1000
- Siderophores, reversed, antimalarial agents, 584
- Sodium channels
 - activator palytoxin, inhibition of tyrosine uptake, adrenal chromaffin cells (bovine), 112
 - photoaffinity labeling of brevetoxin receptor, brain synaptosomes (rat), 988
 - type IIA, voltage-dependent inhibition, mammalian cell line (rat), 756
- Sparteine
 - neuronal cytochrome P450IID1, 63
 - nicotinic acetylcholine receptors, neurons, superior cervical ganglion (rat), 180
- Species differences, cytochrome P450 IIIA-dependent metabolism, digitoxin, toxicity in mammals, 859
- Spinal cord, GABA_A receptor complexes, steroid modulation (rat), 995
- Spin traps, nifedipine and nimodipine (rat), 435
- Spironolactone, -mediated destruction, 17 α -hydroxylase, adrenal cytochrome P-450 (guinea pig), 321
- Steroidogenesis, 17 α -hydroxylase, spironolactone-mediated destruction, adrenal cytochrome P-450 (guinea pig), 321
- Steroids, modulation, GABA_A receptor complexes, frontal cortex and spinal cord (rat), 995
- 2-Styrylquinazolin-4(3*H*)-one, derivatives, interaction of tubulin, 827
- Superoxide, generation and locomotion, phosphofructokinase inactivation by auranofin, neutrophils (human), 427
- Synaptosomes, brain, photoaffinity labeling, brevetoxin receptor (rat), 988
- T**
- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
 - 17 β -estradiol-induced glucose metabolism, breast cancer cells, 1029
 - α -naphthoflavone as an antagonist, formation of inactive complex, Ah receptor (mouse), 607
- Tetraethylammonium, internal and external, block patterns, homologous K⁺ channels, 299
- Tetrahydrocannabinol
 - inhibition of arachidonic acid acylation, phospholipids and triacylglycerols, cerebral cortex (guinea pig), 547
 - major hepatic cannabinoid hydroxylase, cytochrome P-450IIC subfamily (mouse), 228
- Tetrodotoxin, -insensitive Na⁺ channel activator palytoxin, inhibition of tyrosine uptake, adrenal chromaffin cells (bovine), 112
- Thapsigargin, role of inositol (1,4,5)trisphosphate, EGF-induced Ca²⁺ signaling, A431 cells, 254
- Thymus, terminal deoxynucleotidyltransferase, 2'-deoxy-6-thioguanosine 5'-triphosphate as substrate, 508
- Tolbutamide hydroxylase, liver microsomal, (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes, 69
- Triacylglycerols, inhibition of arachidonic acid acylation, tetrahydrocannabinol, cerebral cortex (guinea pig), 547
- Trichosporin-B-III, Ca²⁺-dependent catecholamine secretion, adrenal medullary chromaffin cells (bovine), 790
- Trifluoroacetylation, liver protein adducts, halothane metabolism (rat), 390
- 3,3'-5-Triiodothyronine, selective inhibition of glucuronidation, 2,2,2-triphenylethyl-UDP (rat), 316
- 2,2,2-Triphenylethyl-UDP, selective inhibition of glucuronidation, hepatocytes (rat), 316
- Tryptophan, ultraviolet photoproducts, dioxin agonists (guinea pig), 674
- Tubulin, interaction with 2-styrylquinazolin-4(3*H*)-one derivatives, 827

Tyrosine hydroxylase

- gene expression and proenkephalin, response to reserpine, adrenal (hamster), 515
 - gene transcription rate, nicotine, adrenal medulla (rat), 193
- Tyrosyl radical, perturbation, prostaglandin H synthase, anticyclooxygenase agents, 833**

U

- Ultraviolet, photoproducts of tryptophan, dioxin agonists (guinea pig), 674**
- Uridine-5'-triphosphate, regulation of phospholipase C, 5'-nucleotide receptor, airway epithelial cells (human), 648**

V

- Vascular cells, muscarinic receptor-mediated prostacyclin, cGMP synthesis (bovine), 101**
- Venom, polypeptide toxins, block, potassium channels (scorpion), 932**
- Verapamil**

- fluorescent derivative, monitoring of activity, multidrug transporter, 490**
- frequency and voltage-dependent inhibition, type IIA Na⁺ channels, mammalian cell line (rat), 756**

W

- Willardine, bromowillardine and, non-*N*-methyl-D-aspartate receptors, postnatal hippocampal neurons (rat), 45**

X

- Xenopus* oocytes, patterns of internal and external tetraethylammonium block, homologous K⁺ channels, 299**

Z

- Zinc, extracellular, negative modulation, γ -aminobutyric acid response (chick), 766**

Newsworthy and timely
articles in your field


MOLECULAR PHARMACOLOGY

Editor: **T. Kendall Harden, PhD**, University of North Carolina
School of Medicine, Chapel Hill, North Carolina

Is your special interest receptors and neurotransmitters... drug
metabolism... antibiotic and anticancer drug actions... or other
areas related to the molecular basis of drug action? If so, you
should be subscribing to **MOLECULAR PHARMACOLOGY**.

The editor's and editorial board's high standards ensure that the
papers you read in **MOLECULAR PHARMACOLOGY** are on the
cutting edge of research on drug action and selective toxicity at the
molecular level. Original applications of biochemistry, biophysics,
genetics, and molecular biology are juxtaposed with innovative
pharmacologic research to elucidate basic problems in pharma-
cology and toxicology, including such areas as molecular mecha-
nisms involved in drug receptor-effector coupling, xenobiotic
metabolism, and antibiotic and anticancer drug action. Start your
subscription today to ensure access to the most newsworthy papers
in your field. **Monthly**

Call toll-free to start your subscription immediately, **1-800-638-6423**
from anywhere in the U.S. or Canada.



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service—enter
your multiyear subscription today!

Molecular Pharmacology (monthly)

- ☐ Individual: \$90/yr ☐ Institutions: \$195/yr
(Please add \$30.00 outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name _____

address _____

city/state/zip _____

Payment options:

- ☐ Check enclosed ☐ Bill me
☐ VISA ☐ MasterCard ☐ American Express

card # _____

signature/P.O. # _____

MD residents, please add 5% sales tax. Subscriptions from outside the US and
Canada must be prepaid, in US dollars only. Rates valid for orders received
before October 31, 1991.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to
countries outside the US may take up to 16 weeks. Airmail rates available upon
request.

Williams & Wilkins

MOL 52724

P.O. Box 23291
Baltimore, Maryland 21203-9990

Broadway House
2-6 Fulham Broadway
London SW6 1AA England

J1006S01



**Copyright © 1991 by the American Society for
Pharmacology and Experimental Therapeutics**

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. T. Kendall Harden, Editor, *Molecular Pharmacology*, CB 7368, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7368, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made. Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. If the submitted manuscript utilizes or makes bibliographic reference to articles in press, copies should be included with the manuscript. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text,

including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baucke, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brien. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7). Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers after such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used ($\times$, $\circ$, $\bullet$, $\square$, $\blacksquare$, $\triangle$, $\blacktriangle$, $\odot$). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.

Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
1968 Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
1971 Steven E. Mayer, *Editor*, Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
1975 George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
1978 Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
1983 Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.
1986 William A. Catterall, *Editor*; Joseph A. Beavo, Mont R. Juchau, Neil M. Nathanson, Daniel R. Storm, Frank F. Vincenzi, *Associate Editors*. University of Washington, Seattle.

INFORMATION TO SUBSCRIBERS

MOLECULAR PHARMACOLOGY is published monthly, two volumes a year, beginning in January & July. Instructions to Authors will be found in every issue.

Correspondence concerning business matters should be addressed to Williams & Wilkins, 428 East Preston St., Baltimore, Maryland 21202-3993 U.S.A.

Correspondence regarding editorial matters should be addressed to the Editor, Dr. T. Kendall Harden, CB 7368, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7368.

Annual Subscription Rates—U. S. A. AND POSSESSIONS: personal, \$100.00; institutional, \$210.00, single copy, \$18.00. FOREIGN: personal, \$130.00; institutional, \$240.00; single copy, \$21.00. (Prices subject to change.) Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial, and private institutions and organizations. Foreign subscribers who wish to have issues sent by air mail may inquire of the publisher for the additional cost. The GST Tax Number for Canadian subscribers is 123394371.

Change of address: Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of single issues.

New subscriptions are entered to begin with the next issue to publish unless instructed otherwise by the subscriber. Subscriptions run for a 12-month period.

To avoid a break in your series, subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

Reprints of individual articles are available *only* from authors.

Microfilm. For availability, inquire of Williams & Wilkins.

Williams & Wilkins, Baltimore, MD 21202-3993 U. S. A.